BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-548. [PMID: 25439696 DOI: 10.1016/s1470-2045(14)70442-5] [Cited by in Crossref: 1814] [Cited by in F6Publishing: 842] [Article Influence: 259.1] [Reference Citation Analysis]
Number Citing Articles
1 Gavriatopoulou M, Fotiou D, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, Dimopoulos MA. How I treat elderly patients with plasma cell dyscrasias. Aging (Albany NY) 2018;10:4248-68. [PMID: 30568029 DOI: 10.18632/aging.101707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Da Vià MC, Ziccheddu B, Maeda A, Bagnoli F, Perrone G, Bolli N. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. Hemasphere 2020;4:e502. [PMID: 33283171 DOI: 10.1097/HS9.0000000000000502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Endo K, Ito T, Nomura J, Murakami K, Kondo S, Satoh T, Fukushi D, Yoshino Y, Sasaki Y, Takasu A, Kogure T, Hirota M, Meguro T, Murakami K, Kameoka J, Satoh K. Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy. Case Rep Gastrointest Med 2021;2021:5533993. [PMID: 34136288 DOI: 10.1155/2021/5533993] [Reference Citation Analysis]
4 Katodritou E, Kyrtsonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalakaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, Hatzimichael E, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol 2018;97:1671-82. [PMID: 29756171 DOI: 10.1007/s00277-018-3361-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Price JG, Niedzwiecki D, Oyekunle T, Arcasoy MO, Champ CE, Kelsey CR, Salama JK, Moravan MJ. Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions. Adv Radiat Oncol 2021;6:100729. [PMID: 34258474 DOI: 10.1016/j.adro.2021.100729] [Reference Citation Analysis]
6 Buege MJ, Do B, Lee HC, Weber DM, Horowitz SB, Feng L, Qing Y, Shank BR. Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. Cancer Treat Res Commun 2019;21:100159. [PMID: 31521048 DOI: 10.1016/j.ctarc.2019.100159] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Harb J, Mennesson N, Lepetit C, Fourny M, Louvois M, Bosseboeuf A, Allain-Maillet S, Decaux O, Moreau C, Tallet A, Piver E, Moreau P, Salle V, Bigot-Corbel E, Hermouet S. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens. Cells 2021;10:438. [PMID: 33669483 DOI: 10.3390/cells10020438] [Reference Citation Analysis]
8 Kormann R, François H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J. Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. PLoS One 2017;12:e0179406. [PMID: 28636627 DOI: 10.1371/journal.pone.0179406] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
9 Usmani SZ, Seifter E. Treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2018;2018:97-102. [PMID: 30504297 DOI: 10.1182/asheducation-2018.1.97] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE. Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. Clin Cancer Res 2017;23:1981-7. [PMID: 27698001 DOI: 10.1158/1078-0432.CCR-16-0235] [Cited by in Crossref: 50] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
11 Jamet B, Zamagni E, Nanni C, Bailly C, Carlier T, Touzeau C, Michaud AV, Moreau P, Bodet-Milin C, Kraeber-Bodere F. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. Int J Mol Sci 2020;21:E5406. [PMID: 32751375 DOI: 10.3390/ijms21155406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015;125:3069-75. [PMID: 25838344 DOI: 10.1182/blood-2014-09-568899] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 22.5] [Reference Citation Analysis]
13 Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020;136:2513-23. [PMID: 32735641 DOI: 10.1182/blood.2020007522] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
14 Koutoulidis V, Papanikolaou N, Moulopoulos LA. Functional and molecular MRI of the bone marrow in multiple myeloma. Br J Radiol 2018;91:20170389. [PMID: 29393672 DOI: 10.1259/bjr.20170389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
15 Fernando RC, de Carvalho F, Leme AFP, Colleoni GWB. Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma. Front Oncol 2021;11:563384. [PMID: 33833982 DOI: 10.3389/fonc.2021.563384] [Reference Citation Analysis]
16 Suehara Y, Takamatsu H, Fukumoto K, Fujisawa M, Narita K, Usui Y, Takeuchi M, Endean K, Matsue K. Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. Cancer Sci 2017;108:187-92. [PMID: 27889936 DOI: 10.1111/cas.13125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 2016;128:2757-64. [PMID: 27742709 DOI: 10.1182/blood-2016-09-692947] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
18 Ozga M, Zhao Q, Benson D, Elder P, Williams N, Bumma N, Rosko A, Chaudhry M, Khan A, Devarakonda S, Kahwash R, Vallakati A, Campbell C, Parikh SV, Almaani S, Prosek J, Bittengle J, Pfund K, LoRusso S, Freimer M, Redder E, Efebera Y, Sharma N. AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. J Clin Med 2020;9:E3778. [PMID: 33238501 DOI: 10.3390/jcm9113778] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bailly C, Chalopin B, Gouard S, Carlier T, Saëc PR, Marionneau-Lambot S, Moreau P, Touzeau C, Kraeber-Bodere F, Bodet-Milin C, Chérel M. ImmunoPET in Multiple Myeloma-What? So What? Now What? Cancers (Basel) 2020;12:E1467. [PMID: 32512883 DOI: 10.3390/cancers12061467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Dass J, Arava S, Mishra PC, Dinda AK, Pati HP. Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study. South Asian J Cancer 2019;8:60-4. [PMID: 30766858 DOI: 10.4103/sajc.sajc_64_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kogan F, Broski SM, Yoon D, Gold GE. Applications of PET-MRI in musculoskeletal disease. J Magn Reson Imaging 2018;48:27-47. [PMID: 29969193 DOI: 10.1002/jmri.26183] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
22 Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M, Ouchi E, Matsue K. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer J 2015;5:e329. [PMID: 26230953 DOI: 10.1038/bcj.2015.57] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
23 Li S, Lim HH, Woo KS, Kim SH, Han JY. A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea. Blood Res 2016;51:122-6. [PMID: 27382557 DOI: 10.5045/br.2016.51.2.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
24 Oduor MA, Lotodo TC, Vik TA, Manyega KM, Loehrer P, Omondi AA, Oguda JO, Asirwa FC. Building a Sustainable Comprehensive Multiple Myeloma Program in Western Kenya. JCO Glob Oncol 2021;7:400-7. [PMID: 33739854 DOI: 10.1200/GO.20.00572] [Reference Citation Analysis]
25 Abid MB, Christopher D, Abid MA, Poon ML, Tan LK, Koh LP, Chng WJ. Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. Bone Marrow Transplant 2017;52:1044-6. [PMID: 28481354 DOI: 10.1038/bmt.2017.77] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Kaplinsky J, Arnaout R. Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samples. Nat Commun 2016;7:11881. [PMID: 27302887 DOI: 10.1038/ncomms11881] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 8.4] [Reference Citation Analysis]
27 Mohamed A, Collins J, Jiang H, Molendijk J, Stoll T, Torta F, Wenk MR, Bird RJ, Marlton P, Mollee P, Markey KA, Hill MM. Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. PLoS One 2020;15:e0227455. [PMID: 31914155 DOI: 10.1371/journal.pone.0227455] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
28 Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, Ocheni S, Theurich S, Kuhr K, Scheckel B, Adams A, Skoetz N. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2019;2019. [PMID: 31765002 DOI: 10.1002/14651858.CD013487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
29 Deulofeu M, Kolářová L, Salvadó V, María Peña-Méndez E, Almáši M, Štork M, Pour L, Boadas-Vaello P, Ševčíková S, Havel J, Vaňhara P. Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. Sci Rep 2019;9:7975. [PMID: 31138828 DOI: 10.1038/s41598-019-44215-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
30 Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Aktas Samur A, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Vià MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM, Anderson KC. ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov 2021;2:338-53. [PMID: 34268498 DOI: 10.1158/2643-3230.bcd-20-0164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gámez B, Edwards CM. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. Curr Osteoporos Rep 2018;16:635-41. [PMID: 30229522 DOI: 10.1007/s11914-018-0479-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
33 Alonso S, Cabrero M, Caballero JC, Dávila J, de la Calle VG, López-Godino O, López-Corral L, Pérez E, Vázquez L, Corral R, Caballero D, Del Cañizo C, Mateos MV. Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. Clin Case Rep 2015;3:370-5. [PMID: 26185631 DOI: 10.1002/ccr3.231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
34 Weisel K, Mateos MV, Gay F, Delforge M, Cook G, Szabo Z, Desgraz R, DeCosta L, Moreau P. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. Leukemia 2021;35:1732-44. [PMID: 33067574 DOI: 10.1038/s41375-020-01049-5] [Reference Citation Analysis]
35 Liu Y, Li K. Solitary plasmacytoma of maxillofacial bones: correlation of CT features with pathological findings. Dentomaxillofac Radiol 2020;49:20190277. [PMID: 31559843 DOI: 10.1259/dmfr.20190277] [Reference Citation Analysis]
36 Cabeçadas J, Martinez D, Andreasen S, Mikkelsen LH, Molina-Urra R, Hall D, Strojan P, Hellquist H, Bandello F, Rinaldo A, Cardesa A, Ferlito A. Lymphomas of the head and neck region: an update.Virchows Arch. 2019;474:649-665. [PMID: 30778677 DOI: 10.1007/s00428-019-02543-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
37 Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 2016;6:e486. [PMID: 27768092 DOI: 10.1038/bcj.2016.100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
38 Matsue K, Kobayashi H, Matsue Y, Abe Y, Narita K, Kitadate A, Takeuchi M. Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma. Blood Adv 2018;2:1032-9. [PMID: 29739774 DOI: 10.1182/bloodadvances.2017014720] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
39 Hamza WM, AlEssa AM. Coincidental light chain induced proximal tubulopathy with lupus nephritis: a case report and review of the literature. J Med Case Rep 2021;15:388. [PMID: 34344460 DOI: 10.1186/s13256-021-02990-4] [Reference Citation Analysis]
40 Ali M, Kowkuntla S, Delloro DJ, Galambos C, Hathi D, Janz S, Shokeen M, Tripathi C, Xu H, Yuk J, Zhan F, Tomasson MH, Bates ML. Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. Am J Physiol Regul Integr Comp Physiol 2019;316:R678-86. [PMID: 30892915 DOI: 10.1152/ajpregu.00388.2018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget 2017;8:24031-44. [PMID: 28199990 DOI: 10.18632/oncotarget.15234] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 12.5] [Reference Citation Analysis]
42 Lee N, Kim SM, Lee Y, Jeong D, Yun J, Ryu S, Yoon SS, Ahn YO, Hwang SM, Lee DS. Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma. PLoS One 2021;16:e0246322. [PMID: 33544757 DOI: 10.1371/journal.pone.0246322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J 2018;8:107. [PMID: 30410066 DOI: 10.1038/s41408-018-0144-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Tripathi K, Ramani VC, Bandari SK, Amin R, Brown EE, Ritchie JP, Stewart MD, Sanderson RD. Heparanase promotes myeloma stemness and in vivo tumorigenesis. Matrix Biol 2020;88:53-68. [PMID: 31812535 DOI: 10.1016/j.matbio.2019.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
45 Saitoh T, Oda T. DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. Cancers (Basel) 2021;13:504. [PMID: 33525741 DOI: 10.3390/cancers13030504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Leung N, Drosou ME, Nasr SH. Dysproteinemias and Glomerular Disease. Clin J Am Soc Nephrol. 2018;13:128-139. [PMID: 29114004 DOI: 10.2215/cjn.00560117] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
47 Vakili Sadeghi M, Sedaghat S. Is 99m Tc-methylene diphosphonate bone scintigraphy a sensitive method for detecting bone lesions in multiple myeloma? Caspian J Intern Med 2018;9:140-3. [PMID: 29732031 DOI: 10.22088/cjim.9.2.140] [Reference Citation Analysis]
48 Manzoni M, Marchica V, Storti P, Ziccheddu B, Sammarelli G, Todaro G, Pelizzoni F, Salerio S, Notarfranchi L, Pompa A, Baldini L, Bolli N, Neri A, Giuliani N, Lionetti M. Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. Cancers (Basel) 2020;12:E1332. [PMID: 32456143 DOI: 10.3390/cancers12051332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
49 Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 2021;14:151. [PMID: 34556161 DOI: 10.1186/s13045-021-01162-7] [Reference Citation Analysis]
50 Narasimhan M, Chinnaswamy R, V Giri GV, Subramani VN. Oral medullary plasmacytoma: Rare case reports. J Oral Maxillofac Pathol 2020;24:S55-8. [PMID: 32189906 DOI: 10.4103/jomfp.JOMFP_37_19] [Reference Citation Analysis]
51 Lu M, Hu Y, Wu Y, Zhou H, Jian Y, Tian Y, Chen W. Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. BMC Med Genomics 2019;12:135. [PMID: 31619233 DOI: 10.1186/s12920-019-0577-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Moreno DF, Pereira A, Tovar N, Cibeira MT, Magnano L, Rozman M, López-Guerra M, Colomer D, Martín-Antonio B, Jiménez-Segura R, Isola I, Rodríguez-Lobato LG, Oliver-Caldés A, Mena MP, Rosiñol L, Bladé J, Fernández de Larrea C. Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. Cancers (Basel) 2021;13:2055. [PMID: 33922804 DOI: 10.3390/cancers13092055] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Cui J, Zou Z, Duan J, Tang W, Li Y, Zhang L, Pan L, Niu T. Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma. Front Immunol 2021;12:671904. [PMID: 34489930 DOI: 10.3389/fimmu.2021.671904] [Reference Citation Analysis]
54 Tarragón B, Ye N, Gallagher M, Sen S, Portolés JM, Wang AY. Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis. Clin Kidney J 2021;14:1894-900. [PMID: 34345412 DOI: 10.1093/ckj/sfaa220] [Reference Citation Analysis]
55 Ichii M, Hosen N. Current Understanding of Myelomatous Mesenchymal Stromal Cells Extended through Advances in Experimental Methods. Cancers (Basel) 2020;13:E25. [PMID: 33374627 DOI: 10.3390/cancers13010025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Tian C, Wang L, Wu L, Zhu L, Xu W, Ye Z, Zhao Z, Wang Y, Zhang Y. Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. Biosci Rep 2018;38:BSR20171697. [PMID: 29685954 DOI: 10.1042/BSR20171697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Chen Y, Quan L, Jia C, Guo Y, Wang X, Zhang Y, Jin Y, Liu A. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma. J Proteome Res 2021;20:2673-86. [PMID: 33650432 DOI: 10.1021/acs.jproteome.1c00007] [Reference Citation Analysis]
58 Tymon-Rosario JR, Shi Y, DiVito J, Aksel SO, Gressel GM. Blastic variant of plasma cell myeloma mimicking squamous cell carcinoma of the uterine cervix in a super-morbidly obese female. Gynecol Oncol Rep 2019;29:34-7. [PMID: 31249854 DOI: 10.1016/j.gore.2019.06.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Zhang H, Deng Q, Li JY, Zhao MF, Li YM. [Clinical characteristics and prognosis of 56 multiple myeloma patients over 70 years of age complicated with other systemic diseases]. Zhonghua Xue Ye Xue Za Zhi 2018;39:866-9. [PMID: 30369211 DOI: 10.3760/cma.j.issn.0253-2727.2018.10.016] [Reference Citation Analysis]
60 Wang Y, Yan Y, Sui Z, Dong B, Zuo L. A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy. Medicine (Baltimore) 2018;97:e9920. [PMID: 29489695 DOI: 10.1097/MD.0000000000009920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C. The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer 2019;19:855. [PMID: 31464608 DOI: 10.1186/s12885-019-6080-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Gallagher KC, Geromes AB, Stokes J, Reddy IA, Lewis JS Jr, Baregamian N. Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report. J Endocr Soc 2018;2:112-6. [PMID: 29359203 DOI: 10.1210/js.2017-00445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Klein EM, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann HW, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers (Basel) 2021;13:4856. [PMID: 34638344 DOI: 10.3390/cancers13194856] [Reference Citation Analysis]
64 Ray GK, Jena RK, Panda T, Sethy S. Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation. Hematol Transfus Cell Ther 2021;43:402-9. [PMID: 32792260 DOI: 10.1016/j.htct.2020.04.011] [Reference Citation Analysis]
65 Fitzpatrick MJ, Nardi V, Sohani AR. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol 2021. [PMID: 33687521 DOI: 10.1007/s00256-021-03754-3] [Reference Citation Analysis]
66 Lambert L, Ourednicek P, Meckova Z, Gavelli G, Straub J, Spicka I. Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure. Oncol Lett 2017;13:2490-4. [PMID: 28454425 DOI: 10.3892/ol.2017.5723] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
67 Sameh Soliman D, Ali M, Akikki S, Ibrahim F, El-Omari H, Al-Sabbagh A, Okar L. Transient Pleural Fluid Infiltration by Clonal Plasma Cells Associated with Pulmonary Tuberculosis. Case Rep Oncol 2020;13:883-91. [PMID: 32884535 DOI: 10.1159/000507984] [Reference Citation Analysis]
68 Geng C, Yang G, Wang H, Zhang Z, Zhou H, Chen W. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma. Biomed Res Int 2021;2021:6689457. [PMID: 34104651 DOI: 10.1155/2021/6689457] [Reference Citation Analysis]
69 Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica 2016;101:396-406. [PMID: 27033237 DOI: 10.3324/haematol.2015.129189] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 16.8] [Reference Citation Analysis]
70 Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018;131:163-73. [PMID: 29183887 DOI: 10.1182/blood-2017-09-807560] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 11.5] [Reference Citation Analysis]
71 Chrzan R, Jurczyszyn A, Urbanik A. Whole-Body Low-Dose Computed Tomography (WBLDCT) in Assessment of Patients with Multiple Myeloma - Pilot Study and Standard Imaging Protocol Suggestion. Pol J Radiol 2017;82:356-63. [PMID: 28740565 DOI: 10.12659/PJR.901742] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
72 Almeida SD, Santinha J, Oliveira FPM, Ip J, Lisitskaya M, Lourenço J, Uysal A, Matos C, João C, Papanikolaou N. Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI. Cancer Imaging 2020;20:6. [PMID: 31931880 DOI: 10.1186/s40644-020-0286-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
73 Ohana N, Rouvio O, Nalbandyan K, Sheinis D, Benharroch D. Classification of Solitary Plasmacytoma, Is it more Intricate than Presently Suggested? A Commentary. J Cancer 2018;9:3894-7. [PMID: 30410592 DOI: 10.7150/jca.26854] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
74 Rögnvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Óskarsson JÞ, Pétursdóttir Í, Sigurðardóttir GÁ, Viðarsson B, Önundarson PT, Agnarsson BA, Sigurðardóttir M, Þorsteinsdóttir I, Ólafsson Í, Þórðardóttir ÁR, Eyþórsson E, Jónsson Á, Björnsson AS, Gunnarsson GÞ, Pálsson R, Indriðason ÓS, Gíslason GK, Ólafsson A, Hákonardóttir GK, Brinkhuis M, Halldórsdóttir SL, Ásgeirsdóttir TL, Steingrímsdóttir H, Danielsen R, Dröfn Wessman I, Kampanis P, Hulcrantz M, Durie BGM, Harding S, Landgren O, Kristinsson SY. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J 2021;11:94. [PMID: 34001889 DOI: 10.1038/s41408-021-00480-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Olesen TB, Andersen IT, Ording AG, Ehrenstein V, Seesaghur A, Helleberg C, Silkjær T, Hernandez RK, Niepel D, Abildgaard N. Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015. Support Care Cancer 2021;29:4501-11. [PMID: 33458807 DOI: 10.1007/s00520-020-05934-8] [Reference Citation Analysis]
76 Marini C, Maia T, Bergantim R, Pires J, Aguiar E, Guimarães JE, Trigo F. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. Ann Hematol 2019;98:369-79. [PMID: 30368589 DOI: 10.1007/s00277-018-3528-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
77 Andersen MN, Andersen NF, Lauridsen KL, Etzerodt A, Sorensen BS, Abildgaard N, Plesner T, Hokland M, Møller HJ. STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS. Cancer Immunol Immunother 2021. [PMID: 34061243 DOI: 10.1007/s00262-021-02952-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Ogawa M, Yokoyama K, Imoto S, Tojo A. Role of Circulating Tumor DNA in Hematological Malignancy. Cancers (Basel) 2021;13:2078. [PMID: 33923024 DOI: 10.3390/cancers13092078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Rosner MH, Perazella MA. Acute kidney injury in the patient with cancer. Kidney Res Clin Pract 2019;38:295-308. [PMID: 31284363 DOI: 10.23876/j.krcp.19.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
80 Manda S, Yimer HA, Noga SJ, Girnius S, Yasenchak CA, Charu V, Lyons R, Aiello J, Bogard K, Ferrari RH, Cherepanov D, Demers B, Lu V, Whidden P, Kambhampati S, Birhiray RE, Jhangiani HS, Boccia R, Rifkin RM. Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clin Lymphoma Myeloma Leuk 2020;20:e910-25. [PMID: 32912820 DOI: 10.1016/j.clml.2020.06.024] [Reference Citation Analysis]
81 Hagen P, D'Souza A, Hari P, Davila O, Zhang MJ, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Leuk Lymphoma 2020;61:3484-92. [PMID: 32865474 DOI: 10.1080/10428194.2020.1811275] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Du J, Lu J, Gao W, Liu J, He H, Li L, Li R, Zhou L, Jiang H, Chen W, Fu W, Hou J. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. Ann Hematol 2020;99:1779-91. [PMID: 32594218 DOI: 10.1007/s00277-020-04162-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, Mobley JA, Zhang Y, Brown EE, Vlodavsky I, Sanderson RD. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 2018;65:104-18. [PMID: 28888912 DOI: 10.1016/j.matbio.2017.09.001] [Cited by in Crossref: 102] [Cited by in F6Publishing: 108] [Article Influence: 25.5] [Reference Citation Analysis]
84 Tan H, Gu J, Xu L, Sun G. Solitary bone plasmacytoma of spine with involvement of adjacent disc space: A case report. Medicine (Baltimore) 2021;100:e27288. [PMID: 34664889 DOI: 10.1097/MD.0000000000027288] [Reference Citation Analysis]
85 Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol 2020;33:101152. [PMID: 32139017 DOI: 10.1016/j.beha.2020.101152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
86 Jin Y, Shang Y, Liu H, Ding L, Tong X, Tu H, Yuan G, Zhou F. A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas. Onco Targets Ther 2019;12:10587-96. [PMID: 31819538 DOI: 10.2147/OTT.S229122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Rasch S, Lund T, Asmussen JT, Lerberg Nielsen A, Faebo Larsen R, Østerheden Andersen M, Abildgaard N. Multiple Myeloma Associated Bone Disease. Cancers (Basel) 2020;12:E2113. [PMID: 32751464 DOI: 10.3390/cancers12082113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
88 Chang WI, Koh HK, Yoon SS, Kim HS, Eom KY, Kim IH. The predictive value of serum myeloma protein in solitary plasmacytoma. Radiat Oncol J 2020;38:129-37. [PMID: 33012156 DOI: 10.3857/roj.2019.00570] [Reference Citation Analysis]
89 Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. What Is New in the Treatment of Smoldering Multiple Myeloma? J Clin Med 2021;10:421. [PMID: 33499196 DOI: 10.3390/jcm10030421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Furube A, Kagiyama N, Ishiguro T, Takaku Y, Kurashima K, Shimizu Y, Takayanagi N. Diffuse alveolar hemorrhage caused by IgA deposition associated with multiple myeloma. Clin Case Rep 2019;7:1049-52. [PMID: 31110743 DOI: 10.1002/ccr3.2151] [Reference Citation Analysis]
91 Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D, Hulme CT, Monahan I, Karunanithi K, Dignum H, Belsham E, Neilson J, Harrison B, Lokare A, Campbell G, Hamblin M, Hawkey P, Whittaker AC, Low E, Dunn JA; TEAMM Trial Management Group and Trial Investigators. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 2019;20:1760-72. [PMID: 31668592 DOI: 10.1016/S1470-2045(19)30506-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 20.5] [Reference Citation Analysis]
92 Leung N, Nasr SH. A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. Clin J Am Soc Nephrol 2016;11:1073-82. [PMID: 26992418 DOI: 10.2215/CJN.10641015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
93 Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, Psaltopoulou T, Salta S, Van Dreden P, Sangare R, Larsen AK, Terpos E, Elalamy I, Dimopoulos MA, Gerotziafas GT. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J 2018;8:102. [PMID: 30405097 DOI: 10.1038/s41408-018-0135-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
94 Harada T, Hideshima T, Anderson KC. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol 2016;104:300-9. [PMID: 27099225 DOI: 10.1007/s12185-016-2008-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
95 Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 2015;5:e296. [PMID: 25794132 DOI: 10.1038/bcj.2015.20] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 10.2] [Reference Citation Analysis]
96 Lee DH, Fung TT, Tabung FK, Marinac CR, Devore EE, Rosner BA, Ghobrial IM, Colditz GA, Giovannucci EL, Birmann BM. Prediagnosis dietary pattern and survival in patients with multiple myeloma. Int J Cancer 2020;147:1823-30. [PMID: 32067221 DOI: 10.1002/ijc.32928] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
97 Ninkovic S, Quach H. Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. Cancers (Basel) 2020;12:E3488. [PMID: 33238653 DOI: 10.3390/cancers12113488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fujino M. The histopathology of myeloma in the bone marrow. J Clin Exp Hematop 2018;58:61-7. [PMID: 29998977 DOI: 10.3960/jslrt.18014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. Haematologica 2018;103:1047-53. [PMID: 29567784 DOI: 10.3324/haematol.2017.177139] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
100 Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Front Immunol 2021;12:720571. [PMID: 34421924 DOI: 10.3389/fimmu.2021.720571] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Engelhardt M, Herget GW, Graziani G, Ihorst G, Reinhardt H, Ajayi S, Knop S, Wasch R. Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. Haematologica 2018;103:755-8. [PMID: 29712821 DOI: 10.3324/haematol.2018.188516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
102 Soliman AM, Lin TS, Mahakkanukrauh P, Das S. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma. Int J Mol Sci 2020;21:E7539. [PMID: 33066062 DOI: 10.3390/ijms21207539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Wu H, Wu Y, Ren L, Zhai W, Jiang Y, Guo S, Tao D, Su C, Chen Z, Jiang H. Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma. Exp Ther Med 2019;17:3291-8. [PMID: 30988704 DOI: 10.3892/etm.2019.7373] [Reference Citation Analysis]
104 Saglam A, Balaban S, Yıldırım T, Erdem Y, Uner A, Büyükaşık Y. Monoclonal gammopathy of renal significance presenting as monotypic plasma cell interstitial nephritis in two patients with Sjögren's syndrome. Virchows Arch 2018;472:865-9. [PMID: 29147924 DOI: 10.1007/s00428-017-2270-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Matsukawa T, Eguchi K, Nishino I, Okada K, Oshimi K, Miyagishima T. Light-chain amyloid myopathy isolated to skeletal muscles: A case report. Clin Case Rep 2020;8:2869-73. [PMID: 33363840 DOI: 10.1002/ccr3.3310] [Reference Citation Analysis]
106 Merz M, Dechow T, Scheytt M, Schmidt C, Hackanson B, Knop S. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann Hematol 2020;99:1709-25. [PMID: 32296915 DOI: 10.1007/s00277-020-04023-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
107 Huang WY, Zou DH, Liu W, An G, Xu Y, Sui WW, Deng SH, Li CW, Liu H, Li J, Qiu LG. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2018;39:496-500. [PMID: 30032568 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.012] [Reference Citation Analysis]
108 Moser-Katz T, Joseph NS, Dhodapkar MV, Lee KP, Boise LH. Game of Bones: How Myeloma Manipulates Its Microenvironment. Front Oncol 2020;10:625199. [PMID: 33634031 DOI: 10.3389/fonc.2020.625199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
109 Özenver N, Dawood M, Fleischer E, Klinger A, Efferth T. Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells. Molecules 2020;25:E3224. [PMID: 32679716 DOI: 10.3390/molecules25143224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
110 Katiyar A, Kaur G, Rani L, Jena L, Singh H, Kumar L, Sharma A, Kaur P, Gupta R. Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Sci Rep 2021;11:10957. [PMID: 34040057 DOI: 10.1038/s41598-021-90424-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Brandelik SC, Krzykalla J, Hielscher T, Hillengass J, Kloth JK, Kauczor HU, Weber MA. [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis]. Radiologe 2018;58:72-8. [PMID: 28905085 DOI: 10.1007/s00117-017-0299-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
112 Daves M, Piccin A, Roccaforte V, Lippi G. Comparison of Freelite and N-Latex serum free light chain assays: a critical review. Biochem Med (Zagreb) 2021;31:030701. [PMID: 34393594 DOI: 10.11613/BM.2021.030701] [Reference Citation Analysis]
113 Hansford BG, Silbermann R. Advanced Imaging of Multiple Myeloma Bone Disease. Front Endocrinol (Lausanne) 2018;9:436. [PMID: 30131767 DOI: 10.3389/fendo.2018.00436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
114 Hathi DK, Engelbach JA, Hillengass J, Veis D, Achilefu S, Garbow JR, Shokeen M. Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy. NMR Biomed 2019;32:e4122. [PMID: 31206946 DOI: 10.1002/nbm.4122] [Reference Citation Analysis]
115 Kobayashi H, Tsushima T, Terao T, Abe Y, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue K. Evaluation of the safety and efficacy of daratumumab outside of clinical trials. Int J Hematol 2019;109:665-72. [PMID: 30963473 DOI: 10.1007/s12185-019-02648-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
116 Tian Y, Zhang Y, Zhu WQ, Chen XL, Zhou HB, Chen WM. Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma. Biomed Res Int 2018;2018:9434637. [PMID: 30599001 DOI: 10.1155/2018/9434637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sanchez E, Smith EJ, Yashar MA, Patil S, Li M, Porter AL, Tanenbaum EJ, Schlossberg RE, Soof CM, Hekmati T, Tang G, Wang CS, Chen H, Berenson JR. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma. Target Oncol 2018;13:39-47. [PMID: 29230672 DOI: 10.1007/s11523-017-0538-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
118 Kitadate A, Terao T, Narita K, Ikeda S, Takahashi Y, Tsushima T, Miura D, Takeuchi M, Takahashi N, Matsue K. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci 2021;112:3645-54. [PMID: 34288263 DOI: 10.1111/cas.15073] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
119 Cardona-Benavides IJ, de Ramón C, Gutiérrez NC. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. Cells 2021;10:336. [PMID: 33562668 DOI: 10.3390/cells10020336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Kang KW, Song JE, Lee BH, Jeon MJ, Yu ES, Kim DS, Lee SR, Sung HJ, Choi CW, Park Y, Kim BS. A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea. Sci Rep 2021;11:18449. [PMID: 34531426 DOI: 10.1038/s41598-021-97664-y] [Reference Citation Analysis]
121 Tietsche de Moraes Hungria V, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J, Arrais C, Avendaño Flores O, Barroso F, Basquiera AL, Cao C, Cugliari MS, Enrico A, Foggliatto LM, Galvez KM, Gomez D, Gomez A, de Iracema D, Farias D, Lopez L, Mantilla WA, Martínez D, Mela MJ, Miguel CE, Ovilla R, Palmer L, Pavlovsky C, Ramos C, Remaggi G, Santucci R, Schusterschitz S, Sossa CL, Tuna-Aguilar E, Vela J, Santos T, de la Mora O, Machnicki G, Fernandez M, Barreyro P. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. J Glob Oncol 2019;5:1-19. [PMID: 31774711 DOI: 10.1200/JGO.19.00025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
122 Liang F, Dong XY, Tang GF, Qi KM, Chen W, Sang W, Sun HY, Cao J, Cheng H, Li DP, Li ZY, Xu KL. [Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:332-7. [PMID: 33979979 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.011] [Reference Citation Analysis]
123 Rajkumar SV, Kumar S. Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc 2016;91:101-19. [PMID: 26763514 DOI: 10.1016/j.mayocp.2015.11.007] [Cited by in Crossref: 234] [Cited by in F6Publishing: 211] [Article Influence: 46.8] [Reference Citation Analysis]
124 Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. Front Immunol 2018;9:2431. [PMID: 30505301 DOI: 10.3389/fimmu.2018.02431] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 18.0] [Reference Citation Analysis]
125 Hussain A, Almenfi HF, Almehdewi AM, Hamza MS, Bhat MS, Vijayashankar NP. Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. Cureus 2019;11:e4716. [PMID: 31355076 DOI: 10.7759/cureus.4716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
126 Yamasaki S, Yoshimoto G, Kohno K, Henzan H, Aoki T, Tanimoto K, Sugio Y, Muta T, Kamimura T, Ohno Y, Ogawa R, Eto T, Nagafuji K, Miyamoto T, Akashi K, Iwasaki H; Fukuoka Blood and Marrow Transplantation Group. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. Int J Hematol 2019;109:98-106. [PMID: 30251131 DOI: 10.1007/s12185-018-2538-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
127 Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43:676-681. [PMID: 28061985 DOI: 10.1053/j.seminoncol.2016.11.004] [Cited by in Crossref: 162] [Cited by in F6Publishing: 161] [Article Influence: 32.4] [Reference Citation Analysis]
128 Kinno R, Osakabe Y, Takahashi S, Kurokawa S, Owan Y, Ono K, Baba Y. Nonsystemic vasculitic neuropathy in a patient with IgG-monoclonal gammopathy of undetermined significance: A case report. Medicine (Baltimore) 2020;99:e19036. [PMID: 32000451 DOI: 10.1097/MD.0000000000019036] [Reference Citation Analysis]
129 Liu Z, Zeng Q, Xiang B. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center. Medicine (Baltimore) 2021;100:e25834. [PMID: 33950994 DOI: 10.1097/MD.0000000000025834] [Reference Citation Analysis]
130 Giralt S, Seifter E. Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2018;2018:103-9. [PMID: 30504298 DOI: 10.1182/asheducation-2018.1.103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere 2021;5:e528. [PMID: 33554050 DOI: 10.1097/HS9.0000000000000528] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
132 Jelinek T, Bezdekova R, Zatopkova M, Burgos L, Simicek M, Sevcikova T, Paiva B, Hajek R. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J 2017;7:e617. [PMID: 29053157 DOI: 10.1038/bcj.2017.90] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
133 Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. Am J Hematol 2020;95:4-9. [PMID: 31612526 DOI: 10.1002/ajh.25657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
134 Stuver R, Petersen A, Guerrero-Garcia TA, Matulonis U, Richardson P, Singh P. Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. Case Rep Hematol 2018;2018:3029650. [PMID: 30345126 DOI: 10.1155/2018/3029650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Bray TJ, Chouhan MD, Punwani S, Bainbridge A, Hall-Craggs MA. Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. Br J Radiol 2018;91:20170344. [PMID: 28936896 DOI: 10.1259/bjr.20170344] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
136 Yao X, Xu Z, Du X. PKP/PVP combine chemotherapy in the treatment of multiple myeloma patients with vertebral pathological fractures: minimum 3-year follow-up of 108 cases. J Orthop Surg Res 2019;14:42. [PMID: 30744644 DOI: 10.1186/s13018-019-1078-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
137 Gödecke V, Schmidt JJ, Bräsen JH, Koenecke C, Haller H. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies]. Internist (Berl) 2019;60:10-22. [PMID: 30635666 DOI: 10.1007/s00108-018-0538-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Sponaas AM, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A. PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS One 2015;10:e0139867. [PMID: 26444869 DOI: 10.1371/journal.pone.0139867] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 7.8] [Reference Citation Analysis]
139 Vu T, Gonsalves W, Kumar S, Dispenzieri A, Lacy MQ, Buadi F, Gertz MA, Rajkumar SV. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J 2015;5:e363. [PMID: 26495860 DOI: 10.1038/bcj.2015.91] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
140 Qin XQ, An G, Li ZJ, Liu LT, Xu Y, Yang LH, Ma YP, Deng SH, Sui WW, Qin Y, Feng XY, Zang MR, Yang WJ, Zhang YR, Yi SH, Wang TY, Lv R, Zou DH, Zhao YZ, Qiu LG. Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. Blood Adv 2019;3:751-60. [PMID: 30833275 DOI: 10.1182/bloodadvances.2018019851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC CardioOncol 2019;1:117-30. [PMID: 34396169 DOI: 10.1016/j.jaccao.2019.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
142 Tagliafico AS, Belgioia L, Bonsignore A, Rossi F, Succio G, Bignotti B, Dominietto A. Subspecialty Second-Opinion in Multiple Myeloma CT: Emphasis on Clinically Significant Lytic Lesions. Medicina (Kaunas). 2020;56. [PMID: 32340143 DOI: 10.3390/medicina56040195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Ishikawa T, Haino A, Seki M, Kurihara T, Hirose T, Imai Y, Ishiguro T, Chou T, Toshima M, Terada H, Nashimoto M. The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker. Noncoding RNA Res 2020;5:37-40. [PMID: 32206739 DOI: 10.1016/j.ncrna.2019.12.001] [Reference Citation Analysis]
144 Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging 2016;11:423-35. [PMID: 27143866 DOI: 10.2147/CIA.S89465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
145 Szudy-Szczyrek A, Mlak R, Mielnik M, Szczyrek M, Nowaczyńska A, Homa-Mlak I, Zmorzyński S, Kuśmierczuk K, Sompor J, Filip A, Małecka-Massalska T, Hus M. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Ann Hematol 2020;99:2881-91. [PMID: 32458064 DOI: 10.1007/s00277-020-04092-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
146 Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging 2017;44:50-62. [PMID: 27573638 DOI: 10.1007/s00259-016-3502-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
147 Oben B, Froyen G, Maclachlan KH, Leongamornlert D, Abascal F, Zheng-Lin B, Yellapantula V, Derkach A, Geerdens E, Diamond BT, Arijs I, Maes B, Vanhees K, Hultcrantz M, Manasanch EE, Kazandjian D, Lesokhin A, Dogan A, Zhang Y, Mikulasova A, Walker B, Morgan G, Campbell PJ, Landgren O, Rummens JL, Bolli N, Maura F. Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun 2021;12:1861. [PMID: 33767199 DOI: 10.1038/s41467-021-22140-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
148 Thorsteinsdottir S, Gislason G, Aspelund T, Sverrisdottir I, Landgren O, Turesson I, Björkholm M, Kristinsson SY. Fractures and survival in multiple myeloma: results from a population-based study. Haematologica 2020;105:1067-73. [PMID: 31792034 DOI: 10.3324/haematol.2019.230011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
149 Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J 2015;5:e364. [PMID: 26495861 DOI: 10.1038/bcj.2015.87] [Cited by in Crossref: 61] [Cited by in F6Publishing: 42] [Article Influence: 10.2] [Reference Citation Analysis]
150 Kyle RA, Larson DR, McPhail ED, Therneau TM, Dispenzieri A, Kumar S, Kapoor P, Cerhan JR, Rajkumar SV. Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc 2018;93:739-46. [PMID: 29656787 DOI: 10.1016/j.mayocp.2018.02.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
151 Juneja R, Pati HP. Approach to the Diagnosis of Amyloidosis. Indian J Hematol Blood Transfus 2020;36:246-53. [PMID: 32425373 DOI: 10.1007/s12288-019-01208-4] [Reference Citation Analysis]
152 Manohar S, Nasr SH, Leung N. Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold. Curr Hematol Malig Rep 2018;13:220-6. [PMID: 29725932 DOI: 10.1007/s11899-018-0451-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
153 Duran-Lozano L, Thorleifsson G, Lopez de Lapuente Portilla A, Niroula A, Went M, Thodberg M, Pertesi M, Ajore R, Cafaro C, Olason PI, Stefansdottir L, Bragi Walters G, Halldorsson GH, Turesson I, Kaiser MF, Weinhold N, Abildgaard N, Andersen NF, Mellqvist UH, Waage A, Juul-Vangsted A, Thorsteinsdottir U, Hansson M, Houlston R, Rafnar T, Stefansson K, Nilsson B. Germline variants at SOHLH2 influence multiple myeloma risk. Blood Cancer J 2021;11:76. [PMID: 33875642 DOI: 10.1038/s41408-021-00468-6] [Reference Citation Analysis]
154 Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, Takahashi N, Wakui H. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol 2017;21:212-27. [PMID: 27116248 DOI: 10.1007/s10157-016-1271-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
155 Kim EB, Yee AJ, Raje N. Treatment of Smoldering Multiple Myeloma: Ready for Prime Time? Cancers (Basel) 2020;12:E1223. [PMID: 32414145 DOI: 10.3390/cancers12051223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
156 Messiou C, Kaiser M. Whole body diffusion weighted MRI--a new view of myeloma. Br J Haematol 2015;171:29-37. [PMID: 26013304 DOI: 10.1111/bjh.13509] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
157 Bosseboeuf A, Mennesson N, Allain-Maillet S, Tallet A, Piver E, Decaux O, Moreau C, Moreau P, Lehours P, Mégraud F, Salle V, Bigot-Corbel E, Harb J, Hermouet S. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1. Cancers (Basel) 2020;12:E1254. [PMID: 32429322 DOI: 10.3390/cancers12051254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
158 Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv 2017;1:1911-8. [PMID: 29296837 DOI: 10.1182/bloodadvances.2017005934] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
159 Iriuchishima H, Maeshima A, Takahashi S, Ishizaki T, Yokohama A, Tsukamoto N, Saitoh T, Murakami H, Handa H. Activin A: a novel urinary biomarker of renal impairment in multiple myeloma. Biosci Rep 2019;39:BSR20190206. [PMID: 31072919 DOI: 10.1042/BSR20190206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
160 Aydin C, Ulas T, Hangul C, Yucel OK, Iltar U, Salim O, Ekinci D, Berker Karauzum S. Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. Indian J Hematol Blood Transfus 2020;36:284-91. [PMID: 32425379 DOI: 10.1007/s12288-019-01215-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Xiang Y, Zhang L, Xiang P, Zhang J. Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations. Front Oncol 2021;11:698197. [PMID: 34307166 DOI: 10.3389/fonc.2021.698197] [Reference Citation Analysis]
162 Chen Z, Li J, Shi X, Wang Y, Xia P, Ye W, Ye W, Qin Y, Li H, Li M, Li X, Wen Y, Chen L. Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome. Ther Adv Hematol 2021;12:2040620720983127. [PMID: 33796233 DOI: 10.1177/2040620720983127] [Reference Citation Analysis]
163 Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv 2018;2:1470-9. [PMID: 29945937 DOI: 10.1182/bloodadvances.2018016998] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
164 Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125:3049-58. [PMID: 25838343 DOI: 10.1182/blood-2014-11-568881] [Cited by in Crossref: 162] [Cited by in F6Publishing: 147] [Article Influence: 27.0] [Reference Citation Analysis]
165 Bao L, Wang Y, Lu M, Chu B, Shi L, Gao S, Fang L, Xiang Q. Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients. Cancer Med 2020;9:8962-9. [PMID: 33145966 DOI: 10.1002/cam4.3594] [Reference Citation Analysis]
166 Ding YH, Li YF. [Progress of clonal hematopoiesis of indeterminate potential]. Zhonghua Xue Ye Xue Za Zhi 2016;37:542-4. [PMID: 27431087 DOI: 10.3760/cma.j.issn.0253-2727.2016.06.023] [Reference Citation Analysis]
167 Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 2018;9:3363. [PMID: 30135448 DOI: 10.1038/s41467-018-05058-y] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 29.3] [Reference Citation Analysis]
168 Galakhoff N, Leven C, Eveillard JR, Tempescul A, Kerspern H, Aubron C, Buors C, Lippert É, Carré JL, Padelli M. A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia. Biochem Med (Zagreb) 2020;30:010801. [PMID: 31839726 DOI: 10.11613/BM.2020.010801] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
169 Qasaimeh MA, Wu YC, Bose S, Menachery A, Talluri S, Gonzalez G, Fulciniti M, Karp JM, Prabhala RH, Karnik R. Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. Sci Rep 2017;7:45681. [PMID: 28374831 DOI: 10.1038/srep45681] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
170 Khan AM, Azar I, Najjar S, Bevington T, Mehdi S. A Case of Aggressive Multiple Myeloma with Extramedullary Involvement of the Female Reproductive System, Thyroid and Breasts. Case Rep Hematol 2019;2019:7348504. [PMID: 31467739 DOI: 10.1155/2019/7348504] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
171 Wang W, Zhang CX, Li ZL, Gong M, Ma YG. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. BMC Cancer 2018;18:650. [PMID: 29890944 DOI: 10.1186/s12885-018-4562-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Czyż J, Małkowski B, Jurczyszyn A, Grząśko N, Łopatto R, Olejniczak M, Czyż A, Jachalska A. 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Contemp Oncol (Pozn) 2019;23:23-31. [PMID: 31061633 DOI: 10.5114/wo.2019.83342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Raje N, Yee AJ. How We Approach Smoldering Multiple Myeloma. J Clin Oncol 2020;38:1119-25. [PMID: 32004107 DOI: 10.1200/JCO.19.02834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
174 Vlummens P, De Veirman K, Menu E, De Bruyne E, Offner F, Vanderkerken K, Maes K. The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Front Genet 2019;10:740. [PMID: 31475039 DOI: 10.3389/fgene.2019.00740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
175 Fotiou D, Dimopoulos MA, Kastritis E. How We Manage Patients with Plasmacytomas. Curr Hematol Malig Rep 2018;13:227-35. [PMID: 29667156 DOI: 10.1007/s11899-018-0452-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
176 Markovic U, Leotta V, Tibullo D, Giubbolini R, Romano A, Del Fabro V, Parrinello NL, Cannizzaro MT, Di Raimondo F, Conticello C. Serum free light chains and multiple myeloma: Is it time to extend their application? Clin Case Rep 2020;8:617-24. [PMID: 32274022 DOI: 10.1002/ccr3.2636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
177 Späth F, Wibom C, Krop EJM, Santamaria AI, Johansson AS, Bergdahl IA, Hultdin J, Vermeulen R, Melin B. Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. Haematologica 2019;104:2456-64. [PMID: 30948485 DOI: 10.3324/haematol.2019.216895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
178 Bray TJP, Singh S, Latifoltojar A, Rajesparan K, Rahman F, Narayanan P, Naaseri S, Lopes A, Bainbridge A, Punwani S, Hall-Craggs MA. Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study. PLoS One 2017;12:e0180562. [PMID: 28672007 DOI: 10.1371/journal.pone.0180562] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
179 Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol 2019;37 Suppl 1:62-5. [PMID: 31187526 DOI: 10.1002/hon.2586] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 22.0] [Reference Citation Analysis]
180 Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv 2018;2:3149-54. [PMID: 30463914 DOI: 10.1182/bloodadvances.2018024794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
181 Miller KC, Gertz MA, Buadi FK, Hayman SR, Wolf RC, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Hogan WJ, Kumar SK. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2019;54:587-94. [PMID: 30116014 DOI: 10.1038/s41409-018-0302-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
182 Liu D, Ke P, Huo L, Hu XH, Fu CC, Li CX, Huang HW, Xue SL, Qiu HY, Wu DP, Ma X. [Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies]. Zhonghua Xue Ye Xue Za Zhi 2018;39:952-5. [PMID: 30486596 DOI: 10.3760/cma.j.issn.0253-2727.2018.11.017] [Reference Citation Analysis]
183 Bridoux F, Cockwell P, Glezerman I, Gutgarts V, Hogan JJ, Jhaveri KD, Joly F, Nasr SH, Sawinski D, Leung N. Kidney injury and disease in patients with haematological malignancies. Nat Rev Nephrol 2021;17:386-401. [PMID: 33785910 DOI: 10.1038/s41581-021-00405-7] [Reference Citation Analysis]
184 Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol 2021;12:667054. [PMID: 34149703 DOI: 10.3389/fimmu.2021.667054] [Reference Citation Analysis]
185 Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm MK, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A. Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. Haematologica 2021;106:1943-56. [PMID: 32354870 DOI: 10.3324/haematol.2019.239913] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
186 Luo TC, Wu LL, Wu H, Lu M, Fu WJ, Du J. [Clinical prognosis analysis of patients with "double hit" multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:918-23. [PMID: 31856440 DOI: 10.3760/cma.j.issn.0253-2727.2019.11.006] [Reference Citation Analysis]
187 Kousios A, Duncan N, Charif R, Roufosse C. Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity. J Am Soc Nephrol 2018;29:2901. [PMID: 30377233 DOI: 10.1681/ASN.2018080864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
188 Ooi MG, de Mel S, Chng WJ. Risk Stratification in Multiple Myeloma. Curr Hematol Malig Rep 2016;11:137-47. [PMID: 26883334 DOI: 10.1007/s11899-016-0307-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
189 Chang CF, Chien WC, Chung CH, Lee JC, Hsu SN, Chen JH. Impact of hemodialysis on the prognosis of multiple myeloma: A nationwide population-based study and single-institute analysis. Oncol Lett 2018;16:1991-2002. [PMID: 30008893 DOI: 10.3892/ol.2018.8857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
190 Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw 2016;14:389-400. [PMID: 27059188 DOI: 10.6004/jnccn.2016.0046] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
191 Marchica V, Toscani D, Corcione A, Bolzoni M, Storti P, Vescovini R, Ferretti E, Dalla Palma B, Vicario E, Accardi F, Mancini C, Martella E, Ribatti D, Vacca A, Pistoia V, Giuliani N. Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. Cancers (Basel) 2019;11:E321. [PMID: 30845779 DOI: 10.3390/cancers11030321] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
192 Yadav P, Sathick IJ, Leung N, Brown EE, Cook M, Sanders PW, Cockwell P. Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. Blood Cancer J 2020;10:28. [PMID: 32127527 DOI: 10.1038/s41408-020-0295-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
193 Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S. Nuances in the Management of Older People With Multiple Myeloma. Curr Hematol Malig Rep 2016;11:241-51. [PMID: 27038805 DOI: 10.1007/s11899-016-0323-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
194 Lopes R, Caetano J, Ferreira B, Barahona F, Carneiro EA, João C. The Immune Microenvironment in Multiple Myeloma: Friend or Foe? Cancers (Basel) 2021;13:625. [PMID: 33562441 DOI: 10.3390/cancers13040625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
195 Caprio C, Sacco A, Giustini V, Roccaro AM. Epigenetic Aberrations in Multiple Myeloma. Cancers (Basel) 2020;12:E2996. [PMID: 33076518 DOI: 10.3390/cancers12102996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
196 Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz MA. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant 2018;24:2360-4. [PMID: 29964192 DOI: 10.1016/j.bbmt.2018.06.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
197 Cho SH, Shin HJ, Jung KS, Kim Y. Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment. Turk J Haematol 2019;36:106-11. [PMID: 31046214 DOI: 10.4274/tjh.galenos.2019.2019.0306] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Slomp A, Peperzak V. Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Front Oncol 2018;8:533. [PMID: 30524962 DOI: 10.3389/fonc.2018.00533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
199 Mohamed M, Alhillan A, Gupta V, Nahum K, Mushtaq A, Zheng M, Hossain MA. Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report. J Med Cases 2019;10:305-8. [PMID: 34434296 DOI: 10.14740/jmc3382] [Reference Citation Analysis]
200 Xu L, Liu J, Huang B, Kuang L, Gu J, Chen M, Zou W, Li J. Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma. Cancer Med 2021;10:1656-67. [PMID: 33527753 DOI: 10.1002/cam4.3762] [Reference Citation Analysis]
201 Argueta C, Kashyap T, Klebanov B, Unger TJ, Guo C, Harrington S, Baloglu E, Lee M, Senapedis W, Shacham S, Landesman Y. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget 2018;9:25529-44. [PMID: 29876006 DOI: 10.18632/oncotarget.25368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
202 Ghai A, Fettig N, Fontana F, DiPersio J, Rettig M, Neal JO, Achilefu S, Shoghi KI, Shokeen M. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET. EJNMMI Res 2021;11:97. [PMID: 34586539 DOI: 10.1186/s13550-021-00840-4] [Reference Citation Analysis]
203 Singh S, Pilavachi E, Dudek A, Bray TJP, Latifoltojar A, Rajesparan K, Punwani S, Hall-Craggs MA. Whole body MRI in multiple myeloma: Optimising image acquisition and read times. PLoS One 2020;15:e0228424. [PMID: 31999774 DOI: 10.1371/journal.pone.0228424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
204 Mersin S, Gedük A, Mehtap Ö, Tarkun P, Ünal S, Polat MG, Aygün K, Yenihayat EM, Albayrak H, Hacıhanifioğlu A. Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients. Turk J Haematol 2021;38:211-7. [PMID: 33947178 DOI: 10.4274/tjh.galenos.2021.2020.0555] [Reference Citation Analysis]
205 Xu J, Wang M, Shen Y, Yan M, Xie W, Wang B, Liu H, Cen X. Effects of Amyloid Light-Chain Amyloidosis on Clinical Characteristics and Prognosis in Multiple Myeloma: A Single-Center Retrospective Study. Cancer Manag Res 2021;13:1343-56. [PMID: 33603480 DOI: 10.2147/CMAR.S287922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
206 Liu J, Xie Y, Guo J, Li X, Wang J, Jiang H, Peng Z, Wang J, Wang S, Li Q, Ye L, Zhong Y, Zhang Q, Liu X, Lonard DM, Wang J, O'Malley BW, Liu Z. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma. Nat Commun 2021;12:1022. [PMID: 33589584 DOI: 10.1038/s41467-021-21386-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
207 Park SY, Kim JM, Kang HJ, Kim M, Han JJ, Maeng CH, Baek SK, Yoon HJ, Kim SY, Kim HJ. Crohn's disease and smoldering multiple myeloma: a case report and literature review. Intest Res 2017;15:249-54. [PMID: 28522957 DOI: 10.5217/ir.2017.15.2.249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
208 Shen J, Du X, Zhao L, Luo H, Xu Z. Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. Oncol Lett 2018;15:10017-25. [PMID: 29928372 DOI: 10.3892/ol.2018.8559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
209 Mufti M, Marathe O. A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor. J Hematol 2018;7:69-71. [PMID: 32300415 DOI: 10.14740/jh380w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Tagliafico AS, Dominietto A, Belgioia L, Campi C, Schenone D, Piana M. Quantitative Imaging and Radiomics in Multiple Myeloma: A Potential Opportunity? Medicina (Kaunas). 2021;57. [PMID: 33494449 DOI: 10.3390/medicina57020094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Martello M, Remondini D, Borsi E, Santacroce B, Procacci M, Pezzi A, Dico FA, Martinelli G, Zamagni E, Tacchetti P, Pantani L, Testoni N, Marzocchi G, Rocchi S, Zannetti BA, Mancuso K, Cavo M, Terragna C. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. Leukemia 2016;30:1869-76. [PMID: 27074969 DOI: 10.1038/leu.2016.77] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
212 Fares S, Hadri H, Rachid M, Moutiqui T, Oukkache B, Quessar A. [Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco]. Pan Afr Med J 2021;39:105. [PMID: 34512841 DOI: 10.11604/pamj.2021.39.105.18994] [Reference Citation Analysis]
213 Awada H, Thapa B, Awada H, Dong J, Gurnari C, Hari P, Dhakal B. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells 2021;10:1961. [PMID: 34440730 DOI: 10.3390/cells10081961] [Reference Citation Analysis]
214 Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 2018;9:1691. [PMID: 29703982 DOI: 10.1038/s41467-018-04001-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 27.7] [Reference Citation Analysis]
215 Chong PSY, Chng WJ, de Mel S. STAT3: A Promising Therapeutic Target in Multiple Myeloma. Cancers (Basel) 2019;11:E731. [PMID: 31130718 DOI: 10.3390/cancers11050731] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
216 Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J 2020;10:94. [PMID: 32989217 DOI: 10.1038/s41408-020-00359-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 28.0] [Reference Citation Analysis]
217 Gu Y, Yuan YH, Xu J, Shi QL, Qu XY, Guo R, Bai H, Xu JD, Li JY, Chen LJ. High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. Oncotarget 2017;8:48350-61. [PMID: 28418851 DOI: 10.18632/oncotarget.16237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
218 Damasceno D, Almeida J, Teodosio C, Sanoja-Flores L, Mayado A, Pérez-Pons A, Puig N, Arana P, Paiva B, Solano F, Romero A, Matarraz S, van den Bossche WBL, Flores-Montero J, Durie B, van Dongen JJM, Orfao A. Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. Cancers (Basel) 2021;13:1454. [PMID: 33810169 DOI: 10.3390/cancers13061454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
219 Ozaki S, Handa H, Koiso H, Saitoh T, Sunami K, Ishida T, Suzuki K, Narita T, Iida S, Nakamura Y, Suzuki K, Nishimura N, Murakami H, Shimizu K. Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. J Cancer Res Clin Oncol 2021. [PMID: 34080068 DOI: 10.1007/s00432-021-03668-6] [Reference Citation Analysis]
220 Ulaner GA, Landgren CO. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol 2020;33:101148. [PMID: 32139013 DOI: 10.1016/j.beha.2020.101148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
221 Kishi S, Obata F, Miki H, Matsuura M, Nishimura K, Tamaki M, Kishi F, Murakami T, Abe H, Nagai K, Abe M, Doi T. Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma. Intern Med 2018;57:3597-602. [PMID: 30101939 DOI: 10.2169/internalmedicine.1323-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
222 Rahat MA, Preis M. Role of microRNA in regulation of myeloma-related angiogenesis and survival. World J Hematol 2016; 5(2): 51-60 [DOI: 10.5315/wjh.v5.i2.51] [Reference Citation Analysis]
223 Mesguich C, Hulin C, Latrabe V, Lascaux A, Bordenave L, Hindié E, Marit G. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. Ann Hematol 2020;99:2869-80. [PMID: 32951093 DOI: 10.1007/s00277-020-04265-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
224 Elsabah H, Soliman DS, Ibrahim F, Al-Sabbagh A, Yassin M, Moustafa A, Nashwan AM, Nawaz Z, ElOmri HM. Plasma Cell Myeloma with an Aggressive Clinical Course and Anaplastic Morphology in a 22-Year-Old Patient: A Case Report and Review of Literature. Am J Case Rep 2020;21:e920489. [PMID: 32152261 DOI: 10.12659/AJCR.920489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Girard LP, Soekojo CY, Ooi M, Poon LM, Chng WJ, de Mel S. Immunoglobulin M Paraproteinaemias. Cancers (Basel) 2020;12:E1688. [PMID: 32630470 DOI: 10.3390/cancers12061688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
226 Koning MT, van Rossum AP, Tiren-Verbeet NL, Burgers JA, Karim AF. Two Independent Hematological malignancies in a B-Cell Deficient Good Syndrome Patient. Rheumatology (Oxford) 2021;60:e126-8. [PMID: 33188420 DOI: 10.1093/rheumatology/keaa666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 David G, Marianela P, Victoria M, Mariana L, Francisco G, Carina DM, Cecilia G, Eloisa R. Spinal cord compression due to a solitary, bulky plasmacytoma of posterior mediastinum. Radiol Case Rep 2021;16:1622-7. [PMID: 33995753 DOI: 10.1016/j.radcr.2021.04.024] [Reference Citation Analysis]
228 Cheng Q, Cai L, Zhang Y, Chen L, Hu Y, Sun C. Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models. Front Oncol 2021;11:639528. [PMID: 33747963 DOI: 10.3389/fonc.2021.639528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
229 Sun Y, Xu Z, Jiang J, Xu T, Xu J, Liu P. High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. Front Oncol 2020;10:563666. [PMID: 33014881 DOI: 10.3389/fonc.2020.563666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
230 Zhang H, Zhang SH, Hu JL, Wu YT, Ma XY, Chen Y, Yu B, Liao S, Huang H, Gao S. Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C. Cancer Commun (Lond) 2021;41:615-30. [PMID: 34048638 DOI: 10.1002/cac2.12163] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Friend NL, Hewett DR, Panagopoulos V, Noll JE, Vandyke K, Mrozik KM, Fitter S, Zannettino ACW. Characterization of the role of Samsn1 loss in multiple myeloma development. FASEB Bioadv 2020;2:554-72. [PMID: 32923989 DOI: 10.1096/fba.2020-00027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Albano D, Bosio G, Treglia G, Giubbini R, Bertagna F. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. Eur J Nucl Med Mol Imaging 2018;45:77-84. [PMID: 28822997 DOI: 10.1007/s00259-017-3810-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
233 Gagliardi A, Carbone C, Russo A, Cuccurullo R, Lucania A, Cioppa PD, Misso G, Caraglia M, Tommasino C, Mastrullo L. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett 2016;12:2363-70. [PMID: 27698801 DOI: 10.3892/ol.2016.4965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
234 Ozga M, Zhao Q, Benson D Jr, Elder P, Williams N, Bumma N, Rosko A, Chaudhry M, Khan A, Devarakonda S, Kahwash R, Vallakati A, Campbell C, Parikh SV, Almaani S, Prosek J, Bittengle J, Pfund K, LoRusso S, Freimer M, Redder E, Efebera Y, Sharma N. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival. Cancer Med 2021;10:965-73. [PMID: 33347707 DOI: 10.1002/cam4.3683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Tathineni P, Cancarevic I, Malik BH. Uncommon Presentations of Multiple Myeloma. Cureus 2020;12:e8400. [PMID: 32637279 DOI: 10.7759/cureus.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
236 Diaz-delCastillo M, Andrews RE, Mandal A, Andersen TL, Chantry AD, Heegaard AM. Bone Pain in Multiple Myeloma (BPMM)-A Protocol for a Prospective, Longitudinal, Observational Study. Cancers (Basel) 2021;13:1596. [PMID: 33808348 DOI: 10.3390/cancers13071596] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
237 Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 2021;11:138. [PMID: 34341335 DOI: 10.1038/s41408-021-00530-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
238 Liu Y, Wen L, Ma L, Kang Y, Liu KY, Huang XJ, Ruan GR, Lu J. MAGE genes: Prognostic indicators in AL amyloidosis patients. J Cell Mol Med 2019;23:5672-8. [PMID: 31222935 DOI: 10.1111/jcmm.14475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
239 Wang J, Chen J, Qiu D, Zeng Z. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma. Int J Mol Med 2021;47:643-58. [PMID: 33416146 DOI: 10.3892/ijmm.2020.4831] [Reference Citation Analysis]
240 Cury PCC, Higashi F, Zacchi FFS, Palhares RB, Quero AA, Dias ALMS, Crusoé EQ, Hungria VTM. Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients. Hematol Transfus Cell Ther 2020;42:159-63. [PMID: 31519532 DOI: 10.1016/j.htct.2019.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
241 Lecouvet FE, Vekemans MC, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, Malghem J, Wuts J, Hillengass J, Vandecaveye V, Jamar F, Gheysens O, Vande Berg BC. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skeletal Radiol 2021. [PMID: 34363522 DOI: 10.1007/s00256-021-03841-5] [Reference Citation Analysis]
242 Nie S, Wang M, Wan Q, Kong Y, Ou J, Jia N, Zhang X, Luo F, Liu X, Wang L, Cao Y, Chen R, Zhao M, Chan DYL, Wang G. Kidney Biopsy in Patients With Monoclonal Gammopathy: A Multicenter Retrospective Cohort Study. Front Med (Lausanne) 2021;8:687149. [PMID: 34109201 DOI: 10.3389/fmed.2021.687149] [Reference Citation Analysis]
243 Cheng CN, Huang SY, Lien PW, Huang ST, Lin FJ. Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan. PLoS One 2021;16:e0252124. [PMID: 34038463 DOI: 10.1371/journal.pone.0252124] [Reference Citation Analysis]
244 Kim SJ, Shin HT, Lee HO, Kim NK, Yun JW, Hwang JH, Kim K, Park WY. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. Oncotarget 2016;7:68350-9. [PMID: 27634910 DOI: 10.18632/oncotarget.12029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
245 González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia 2016;30:2026-31. [PMID: 27133826 DOI: 10.1038/leu.2016.123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
246 Gautam A, Sahu KK, Alamgir A, Siddiqi I, Ailawadhi S. Extramedullary Solitary Plasmacytoma: Demonstrating the Role of 18F-FDG PET Imaging. J Clin Diagn Res 2017;11:XD01-3. [PMID: 28571247 DOI: 10.7860/JCDR/2017/22801.9557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
247 Karampinos DC, Ruschke S, Dieckmeyer M, Diefenbach M, Franz D, Gersing AS, Krug R, Baum T. Quantitative MRI and spectroscopy of bone marrow. J Magn Reson Imaging 2018;47:332-53. [PMID: 28570033 DOI: 10.1002/jmri.25769] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 22.5] [Reference Citation Analysis]
248 Fiala MA, Dukeman J, Tuchman SA, Keller M, Vij R, Wildes TM. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. JCO Clin Cancer Inform 2017;1. [PMID: 30547156 DOI: 10.1200/CCI.17.00089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
249 Napodano C, Gulli F, Rapaccini GL, Marino M, Basile U. Cryoglobulins: Identification, classification, and novel biomarkers of mysterious proteins. Adv Clin Chem 2021;104:299-340. [PMID: 34462057 DOI: 10.1016/bs.acc.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
250 Jain A, Haynes R, Kothari J, Khera A, Soares M, Ramasamy K. Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Adv 2019;3:2409-23. [PMID: 31409583 DOI: 10.1182/bloodadvances.2019031914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
251 Kostopoulos IV, Eleutherakis-Papaiakovou E, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Orologas-Stavrou N, Kanellias N, Malandrakis P, Liacos CI, Papaioannou NE, Papanota AM, Migkou M, Fotiou D, Gavriatopoulou M, Angelis NV, Kastritis E, Dimopoulos MA, Tsitsilonis OE, Terpos E. Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. Cancers (Basel) 2021;13:4047. [PMID: 34439201 DOI: 10.3390/cancers13164047] [Reference Citation Analysis]
252 Schneiderova P, Pika T, Gajdos P, Fillerova R, Kromer P, Kudelka M, Minarik J, Papajik T, Scudla V, Kriegova E. Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget 2017;8:69408-21. [PMID: 29050213 DOI: 10.18632/oncotarget.11242] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
253 Fichou N, Gouard S, Maurel C, Barbet J, Ferrer L, Morgenstern A, Bruchertseifer F, Faivre-Chauvet A, Bigot-Corbel E, Davodeau F, Gaschet J, Chérel M. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. Front Med (Lausanne) 2015;2:76. [PMID: 26582128 DOI: 10.3389/fmed.2015.00076] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
254 Garrido DI, Bove V, Matosas V, Riva E. Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population. Med Pharm Rep 2021;94:48-52. [PMID: 33629048 DOI: 10.15386/mpr-1750] [Reference Citation Analysis]
255 Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P. Insights on Multiple Myeloma Treatment Strategies. Hemasphere 2019;3:e163. [PMID: 31723802 DOI: 10.1097/HS9.0000000000000163] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
256 Joseph A, Harel S, Venot M, Valade S, Mariotte E, Pichereau C, Chermak A, Zafrani L, Azoulay E, Canet E. Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. Clin Kidney J 2018;11:20-5. [PMID: 29423196 DOI: 10.1093/ckj/sfx059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
257 Gran C, Liwing J, Wagner AK, Verhoek A, Gezin A, Alici E, Nahi H. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. Am J Hematol 2021;96:23-30. [PMID: 32936979 DOI: 10.1002/ajh.25999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Lamarthée B, de Vassoigne F, Malard F, Stocker N, Boussen I, Médiavilla C, Tang R, Fava F, Garderet L, Marjanovic Z, Brissot E, Mohty M, Gaugler B. Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma. Oncoimmunology 2018;7:e1444411. [PMID: 29900053 DOI: 10.1080/2162402X.2018.1444411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
259 Mayne ES, Tait M, Jacobson BF, Pillay E, Louw SJ. Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report. Thromb J 2018;16:30. [PMID: 30534006 DOI: 10.1186/s12959-018-0184-2] [Reference Citation Analysis]
260 Madhira BR, Konala VM, Adapa S, Naramala S, Ravella PM, Parikh K, Gentile TC. Recent Advances in the Management of Smoldering Multiple Myeloma. World J Oncol 2020;11:45-54. [PMID: 32284772 DOI: 10.14740/wjon1245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 2018;25:62-7. [PMID: 29424556 DOI: 10.1080/13506129.2018.1436048] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
262 Shahinian VB, Bahl A, Niepel D, Lorusso V. Considering renal risk while managing cancer. Cancer Manag Res 2017;9:167-78. [PMID: 28553142 DOI: 10.2147/CMAR.S125864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
263 Nozza A. POEMS SYNDROME: an Update. Mediterr J Hematol Infect Dis 2017;9:e2017051. [PMID: 28894560 DOI: 10.4084/MJHID.2017.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
264 Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:719-34. [PMID: 27291302 DOI: 10.1002/ajh.24402] [Cited by in Crossref: 241] [Cited by in F6Publishing: 228] [Article Influence: 60.3] [Reference Citation Analysis]
265 Zhou X, Steinhardt MJ, Grathwohl D, Meckel K, Nickel K, Leicht HB, Krummenast F, Einsele H, Rasche L, Kortüm KM. Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. Cancer Med 2020;9:5819-26. [PMID: 32608149 DOI: 10.1002/cam4.3209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
266 Zangari M, Suva LJ. The effects of proteasome inhibitors on bone remodeling in multiple myeloma. Bone 2016;86:131-8. [PMID: 26947893 DOI: 10.1016/j.bone.2016.02.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
267 Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int 2016;113:470-6. [PMID: 27476706 DOI: 10.3238/arztebl.2016.0470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
268 Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018;378:241-9. [PMID: 29342381 DOI: 10.1056/NEJMoa1709974] [Cited by in Crossref: 188] [Cited by in F6Publishing: 89] [Article Influence: 62.7] [Reference Citation Analysis]
269 Touzeau C, Le Gouill S, Mahé B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica 2017;102:e112-4. [PMID: 28057737 DOI: 10.3324/haematol.2016.160408] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
270 Yao WQ, Zhu MQ, Yan LZ, Jin S, Shang JJ, Yao Y, Yan S, Liu Y, Wu DP, Fu CC. [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:720-5. [PMID: 31648471 DOI: 10.3760/cma.j.issn.0253-2727.2019.09.002] [Reference Citation Analysis]
271 Park HY, Kim KW, Yoon MA, Lee MH, Chae EJ, Lee JH, Chung HW, Yoon DH. Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging 2020;20:14. [PMID: 32000858 DOI: 10.1186/s40644-020-0293-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
272 Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J 2018;8:125. [PMID: 30538223 DOI: 10.1038/s41408-018-0163-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
273 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Osório RM, Pina S, Salero T, Coelho MV, Sousa D, Mendonça C. Association of Multiple Myeloma and Giant Cell Arteritis - A Case Report. Eur J Case Rep Intern Med 2020;7:001360. [PMID: 32015971 DOI: 10.12890/2020_001360] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
275 Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018;8:117. [PMID: 30455467 DOI: 10.1038/s41408-018-0153-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
276 Yang Y, Chen L, Jia Y, Liu Y, Wen L, Liang Y, An Y, Chen S, Su Y, Li Z. Monoclonal gammopathy in rheumatic diseases. Clin Rheumatol 2018;37:1751-62. [PMID: 29532268 DOI: 10.1007/s10067-018-4064-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
277 Jasiński M, Basak GW, Jedrzejczak WW. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma. Front Immunol 2021;12:632937. [PMID: 33717171 DOI: 10.3389/fimmu.2021.632937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
278 Udongwo N, Douedi S, Odak M, Alshami A, Patel SV, Farooq T. Atypical Presentation of Plasma Cell Neoplasm of the Sternum. Cureus 2021;13:e16106. [PMID: 34350073 DOI: 10.7759/cureus.16106] [Reference Citation Analysis]
279 Larsen JT, Kumar S. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther 2015;3:47-68. [PMID: 27182478 DOI: 10.1007/s40487-015-0009-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
280 Ghandili S, Schönlein M, Lütgehetmann M, Schulze Zur Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel KC, Leypoldt LB. Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers (Basel) 2021;13:3800. [PMID: 34359701 DOI: 10.3390/cancers13153800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol 2020;38:1126-37. [PMID: 31652094 DOI: 10.1200/JCO.19.01740] [Cited by in Crossref: 62] [Cited by in F6Publishing: 39] [Article Influence: 31.0] [Reference Citation Analysis]
282 Cerqueira A, Seco T, Paiva D, Martins H, Cotter J. Acute Kidney Failure: When Multiple Myeloma Doesn´t Give Additional Clues. Cureus 2020;12:e7664. [PMID: 32419992 DOI: 10.7759/cureus.7664] [Reference Citation Analysis]
283 Díaz-Tejedor A, Lorenzo-Mohamed M, Puig N, García-Sanz R, Mateos MV, Garayoa M, Paíno T. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers (Basel) 2021;13:1353. [PMID: 33802806 DOI: 10.3390/cancers13061353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
284 Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, Jagannath S, Parekh S, Madduri D. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol 2020;13:94. [PMID: 32664919 DOI: 10.1186/s13045-020-00934-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 48.0] [Reference Citation Analysis]
285 Agbuduwe C, Yang H, Gaglani J, Ajithkumar T. Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. Clin Med (Lond) 2020;20:e191-5. [PMID: 32934063 DOI: 10.7861/clinmed.2019-0488] [Reference Citation Analysis]
286 Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. Blood Cancer J 2021;11:17. [PMID: 33563896 DOI: 10.1038/s41408-021-00419-1] [Reference Citation Analysis]
287 Vicentini JRT, Bredella MA. Role of FDG PET in the staging of multiple myeloma. Skeletal Radiol 2021. [PMID: 33813607 DOI: 10.1007/s00256-021-03771-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 VanValkenburg ME, Pruitt GI, Brill IK, Costa L, Ehtsham M, Justement IT, Innis-Shelton RD, Salzman D, Reddy ES, Godby KN, Mikhail FM, Carroll AJ, Reddy VB, Sanderson RD, Justement LB, Sanders PW, Brown EE. Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. Cancer Causes Control 2016;27:81-91. [PMID: 26596855 DOI: 10.1007/s10552-015-0685-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
289 Chen L, Li Z, Li S, Fu W, Li R. Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials. J Cancer 2020;11:2639-44. [PMID: 32201534 DOI: 10.7150/jca.40711] [Reference Citation Analysis]
290 Seesaghur A, Petruski-Ivleva N, Banks V, Wang JR, Mattox P, Hoeben E, Maskell J, Neasham D, Reynolds SL, Kafatos G. Real-world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK-based electronic health records database. Pharmacoepidemiol Drug Saf 2021;30:248-56. [PMID: 33174338 DOI: 10.1002/pds.5171] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
291 Cigliana G, Gulli F, Napodano C, Pocino K, De Santis E, Colacicco L, Cordone I, Conti L, Basile U. Serum free light chain quantitative assays: Dilemma of a biomarker. J Clin Lab Anal 2018;32. [PMID: 28444965 DOI: 10.1002/jcla.22243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
292 Smith JD, Wijeratne N, Schneider HG, de Malmanche T, Hissaria P, Toit SD, Chiu W, Boyder C, Morison IM, Tseng A, Glegg K, Wienholt L, Mollee P. Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clin Biochem Rev 2021;42:11-6. [PMID: 34305209 DOI: 10.33176/AACB-21-00001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Mathur P, Alapat D, Kumar M, Thanendrarajan S. Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma. Clin Case Rep 2018;6:269-73. [PMID: 29445461 DOI: 10.1002/ccr3.1308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
294 Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood 2019;134:668-77. [PMID: 31270103 DOI: 10.1182/blood.2019000667] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 24.5] [Reference Citation Analysis]
295 Ullah A, Omar N, Savage NM, Bollag RJ, Singh G. Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody. Pract Lab Med 2021;26:e00240. [PMID: 34124325 DOI: 10.1016/j.plabm.2021.e00240] [Reference Citation Analysis]
296 Evans HR, Karmakharm T, Lawson MA, Walker RE, Harris W, Fellows C, Huggins ID, Richmond P, Chantry AD. Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. Bone 2016;83:9-16. [PMID: 26456145 DOI: 10.1016/j.bone.2015.10.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
297 Lai AYT, Riddell A, Barwick T, Boyd K, Rockall A, Kaiser M, Koh DM, Saffar H, Yusuf S, Messiou C. Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. Eur Radiol 2020;30:320-7. [PMID: 31267214 DOI: 10.1007/s00330-019-06281-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
298 Soodgupta D, Zhou H, Beaino W, Lu L, Rettig M, Snee M, Skeath J, DiPersio JF, Akers WJ, Laforest R, Anderson CJ, Tomasson MH, Shokeen M. Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. J Nucl Med 2016;57:640-5. [PMID: 26742713 DOI: 10.2967/jnumed.115.164624] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
299 Medina A, Puig N, Flores-Montero J, Jimenez C, Sarasquete ME, Garcia-Alvarez M, Prieto-Conde I, Chillon C, Alcoceba M, Gutierrez NC, Oriol A, Rosinol L, Bladè J, Gironella M, Hernandez MT, Gonzalez-Calle V, Cedena MT, Paiva B, San-Miguel JF, Lahuerta JJ, Mateos MV, Martinez-Lopez J, Orfao A, Gonzalez M, Garcia-Sanz R. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J 2020;10:108. [PMID: 33127891 DOI: 10.1038/s41408-020-00377-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
300 Soliman AM, Das S, Teoh SL. Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis. Int J Mol Sci 2021;22:7470. [PMID: 34299097 DOI: 10.3390/ijms22147470] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Salguero DA, Barletta PA, Sierraalta W. Severe abdominal pain and diarrhea - unusual multiple myeloma presentation with a severe prognosis: a case report. J Med Case Rep 2018;12:70. [PMID: 29549883 DOI: 10.1186/s13256-018-1598-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Kreutzer EP, Sauer S, Kriegsmann M, Staemmler H, Egerer G, Kriegsmann K. Accuracy and Reliability of Internet Resources for Information on Monoclonal Gammopathy of Undetermined Significance-What Information Is out There for Our Patients? Cancers (Basel) 2021;13:4508. [PMID: 34572733 DOI: 10.3390/cancers13184508] [Reference Citation Analysis]
303 Manyega KM, Lotodo TC, Oduor MA, Namaemba DF, Omondi AA, Oyolo YL, Oguda J, Loehrer PJ, Vik TA, Asirwa FC. Retrospective Analysis of Presentation, Treatment, and Outcomes of Multiple Myeloma at a Large Public Referral Hospital in Eldoret, Kenya. JCO Glob Oncol 2021;7:391-9. [PMID: 33729826 DOI: 10.1200/GO.20.00573] [Reference Citation Analysis]
304 Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, Wu J, Wang Y, Wang J, Yan H, Xu WB, Jiang H, Du J, Ding XY, Li B, Li JM, Fu WJ, Zhu J, Zhu L, Chen Z, Fan XF, Hou J, Li JY, Mi JQ, Chen SJ. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A 2019;116:9543-51. [PMID: 30988175 DOI: 10.1073/pnas.1819745116] [Cited by in Crossref: 123] [Cited by in F6Publishing: 117] [Article Influence: 61.5] [Reference Citation Analysis]
305 Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2019;54:2039-50. [PMID: 31190005 DOI: 10.1038/s41409-019-0590-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
306 Yıkılmaz AŞ, Akinci S, Bakanay ŞM, Dilek İ. VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience. Int J Hematol Oncol Stem Cell Res 2020;14:248-56. [PMID: 33603986 DOI: 10.18502/ijhoscr.v14i4.4481] [Reference Citation Analysis]
307 Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M. Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV). J Cancer Res Clin Oncol 2021;147:2349-59. [PMID: 33433659 DOI: 10.1007/s00432-020-03504-3] [Reference Citation Analysis]
308 Egan P, Drain S, Conway C, Bjourson AJ, Alexander HD. Towards Stratified Medicine in Plasma Cell Myeloma. Int J Mol Sci 2016;17:E1760. [PMID: 27775669 DOI: 10.3390/ijms17101760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv 2019;3:744-50. [PMID: 30824418 DOI: 10.1182/bloodadvances.2018022806] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
310 Xiong X, Wang J, Hu S, Dai Y, Zhang Y, Hu C. Differentiating Between Multiple Myeloma and Metastasis Subtypes of Lumbar Vertebra Lesions Using Machine Learning-Based Radiomics. Front Oncol. 2021;11:601699. [PMID: 33718148 DOI: 10.3389/fonc.2021.601699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
311 Wu D, Miao J, Hu J, Li F, Gao D, Chen H, Feng Y, Shen Y, He A. PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib. Front Oncol 2021;11:684232. [PMID: 34367968 DOI: 10.3389/fonc.2021.684232] [Reference Citation Analysis]
312 Ali M, Lemonakis K, Wihlborg AK, Veskovski L, Turesson I, Mellqvist UH, Gullberg U, Hansson M, Nilsson B. Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden. Blood Cancer J 2019;9:57. [PMID: 31363079 DOI: 10.1038/s41408-019-0222-8] [Reference Citation Analysis]
313 Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa L, Kourelis TV, Kyle RA, Gertz MA, Kumar SK. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia 2017;31:130-5. [PMID: 27457702 DOI: 10.1038/leu.2016.205] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
314 Sundararajan S, Kumar A, Korde N, Agarwal A. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. Curr Hematol Malig Rep 2016;11:102-10. [PMID: 26894382 DOI: 10.1007/s11899-016-0305-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
315 Hewett DR, Vandyke K, Lawrence DM, Friend N, Noll JE, Geoghegan JM, Croucher PI, Zannettino ACW. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. Neoplasia 2017;19:972-81. [PMID: 29091798 DOI: 10.1016/j.neo.2017.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
316 Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia 2019;33:1273-7. [PMID: 30787429 DOI: 10.1038/s41375-019-0419-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
317 Isidori A, de Leval L, Gergis U, Musto P, Porcu P. Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. Front Oncol 2020;10:1439. [PMID: 32923397 DOI: 10.3389/fonc.2020.01439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
318 Wang Q, Zhao D, Xian M, Wang Z, Bi E, Su P, Qian J, Ma X, Yang M, Liu L, Zu Y, Pingali SR, Chen K, Cai Z, Yi Q. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood 2020;136:2557-73. [PMID: 32582913 DOI: 10.1182/blood.2020005795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
319 Takasu M, Kondo S, Akiyama Y, Takahashi Y, Maeda S, Baba Y, Kawase T, Ichinohe T, Awai K. Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI. PLoS One 2020;15:e0229607. [PMID: 32106239 DOI: 10.1371/journal.pone.0229607] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
320 Steinmetz HT, Singh M, Lebioda A, Gonzalez-McQuire S, Rieth A, Schoehl M, Poenisch W. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany. Oncol Res Treat 2020;43:449-59. [PMID: 32694243 DOI: 10.1159/000509018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
321 Yan L, Shang J, Shi X, Kang H, Liu W, Xu N, Liu Y, Chen G, Kang L, Gong F, Tang F, Yu L, Wu D, Fu C. Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells. Am J Hematol 2020;95:E20-3. [PMID: 31637745 DOI: 10.1002/ajh.25664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S; TOURMALINE-MM4 study group. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol 2020;38:4030-41. [PMID: 33021870 DOI: 10.1200/JCO.20.02060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
323 Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J 2018;8:59. [PMID: 29895887 DOI: 10.1038/s41408-018-0077-4] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 28.3] [Reference Citation Analysis]
324 Saikia TK. Developments in the Field of Myeloma in the Last Decade. Indian J Hematol Blood Transfus 2017;33:3-7. [PMID: 28194049 DOI: 10.1007/s12288-017-0777-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
325 Byun JM, Kwon YN, Koh Y, Yoon SS, Sung JJ, Kim I. Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders. Sci Rep 2019;9:16769. [PMID: 31727997 DOI: 10.1038/s41598-019-53289-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
326 Reddy A, Rapiti N, Gounden V. Comparison of 24-hour versus random urine samples for determination and quantification of Bence Jones protein in a South African population. Afr J Lab Med 2021;10:1228. [PMID: 34522630 DOI: 10.4102/ajlm.v10i1.1228] [Reference Citation Analysis]
327 Stumpf U, Hesse E, Böcker W, Kammerlander C, Neuerburg C, Schmidmaier R. [Differential diagnoses of osteoporosis]. Z Gerontol Geriatr 2019;52:414-20. [PMID: 31297588 DOI: 10.1007/s00391-019-01571-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Qin X, Lin L, Cao L, Zhang X, Song X, Hao J, Zhang Y, Wei R, Huang X, Lu J, Ge Q. Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis. Sci Rep. 2017;7:45305. [PMID: 28345605 DOI: 10.1038/srep45305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
329 Papanota AM, Tsiakanikas P, Kontos CK, Malandrakis P, Liacos CI, Ntanasis-Stathopoulos I, Kanellias N, Gavriatopoulou M, Kastritis E, Avgeris M, Dimopoulos MA, Scorilas A, Terpos E. A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. Cancers (Basel) 2021;13:3877. [PMID: 34359778 DOI: 10.3390/cancers13153877] [Reference Citation Analysis]
330 Yang Y, Han X, Zheng G, Cai Z. Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. Health Sci Rep 2019;2:e113. [PMID: 31049418 DOI: 10.1002/hsr2.113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
331 Michaud-Robert AV, Jamet B, Bailly C, Carlier T, Moreau P, Touzeau C, Bourgeois M, Kraeber-Bodere F, Bodet-Milin C. FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients? Cancers (Basel) 2020;12:E1384. [PMID: 32481533 DOI: 10.3390/cancers12061384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 2016;6:e396. [PMID: 26871714 DOI: 10.1038/bcj.2016.4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
333 Elnair RA, Holstein SA. Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs 2021;81:825-40. [PMID: 33871818 DOI: 10.1007/s40265-021-01514-0] [Reference Citation Analysis]
334 Alhallak K, Jeske A, de la Puente P, Sun J, Fiala M, Azab F, Muz B, Sahin I, Vij R, DiPersio JF, Azab AK. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Sci Rep 2021;11:19343. [PMID: 34588522 DOI: 10.1038/s41598-021-98760-9] [Reference Citation Analysis]
335 Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J 2015;5:e365. [PMID: 26517360 DOI: 10.1038/bcj.2015.92] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
336 Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol 2018;11:10. [PMID: 29338789 DOI: 10.1186/s13045-017-0549-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 20.3] [Reference Citation Analysis]
337 Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology 2016;5:e1093721. [PMID: 27141379 DOI: 10.1080/2162402X.2015.1093721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
338 Yadav P, Cook M, Cockwell P. Current Trends of Renal Impairment in Multiple Myeloma. Kidney Dis (Basel) 2016;1:241-57. [PMID: 27536684 DOI: 10.1159/000442511] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
339 Mansilla C, Soria E, Vallejo M, Valiente A, Perez-Juana A, Zabalza A, Hurtado G, Sala F, Ramírez N. Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma. Transl Oncol 2018;11:647-52. [PMID: 29604510 DOI: 10.1016/j.tranon.2018.02.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
340 Rosko AE, Hade EM, Li W, Ing S, Jackson RD, Paskett ED, Naughton MJ. Bone Health and Survival in Women With Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2018;18:597-602.e1. [PMID: 30049515 DOI: 10.1016/j.clml.2018.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Fonseca R, Hagiwara M, Panjabi S, Yucel E, Buchanan J, Delea T. Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer J 2021;11:35. [PMID: 33941766 DOI: 10.1038/s41408-021-00431-5] [Reference Citation Analysis]
342 Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Arch 2020;476:337-51. [PMID: 31848687 DOI: 10.1007/s00428-019-02725-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
343 Yadav P, Merz M, Mai EK, Försti A, Jauch A, Goldschmidt H, Hemminki K. Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. Haematologica 2018;103:e162-4. [PMID: 29419430 DOI: 10.3324/haematol.2017.184226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
344 Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, Touzeau C, Moreau P, Chérel M, Kraeber-Bodéré F, Bodet-Milin C. PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. Int J Mol Sci 2017;18:E445. [PMID: 28218709 DOI: 10.3390/ijms18020445] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
345 Panero J, Stella F, Schutz N, Fantl DB, Slavutsky I. Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders. PLoS One 2015;10:e0137972. [PMID: 26366868 DOI: 10.1371/journal.pone.0137972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
346 Dabrowski P, Kulus MJ, Cieslik A, Domagala Z, Wiglusz RJ, Kuropka P, Kuryszko J, Thannhauser A, Szleszkowski L, Wojtulek PM, Solinski D, Dziegiel P. A Case of Syphilis with High Bone Arsenic Concentration from Early Modern Cemetery (Wroclaw, Poland). Open Life Sci 2019;14:427-39. [PMID: 33817178 DOI: 10.1515/biol-2019-0048] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
347 Marcussen M, Bødker JS, Christensen HS, Johansen P, Nielsen S, Christiansen I, Bergmann OJ, Bøgsted M, Dybkær K, Vyberg M, Johnsen HE. Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa. PLoS One 2017;12:e0169286. [PMID: 28052121 DOI: 10.1371/journal.pone.0169286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
348 Wu Q, Liu JR, Huang BH, Zou WY, Gu JL, Chen ML, Kuang LF, Zheng D, Xu DR, Zhou ZH, Wang HH, Su C, Tong XZ, Li J. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center]. Zhonghua Xue Ye Xue Za Zhi 2019;40:453-9. [PMID: 31340616 DOI: 10.3760/cma.j.issn.0253-2727.2019.06.002] [Reference Citation Analysis]
349 Maatouk I, He S, Becker N, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Schellberg D, Herzog W, Hillengass J. Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. BMJ Open 2018;8:e021376. [PMID: 30061438 DOI: 10.1136/bmjopen-2017-021376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
350 Dupuis MM, Tuchman SA. Non-secretory multiple myeloma: from biology to clinical management. Onco Targets Ther 2016;9:7583-90. [PMID: 28008276 DOI: 10.2147/OTT.S122241] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 4.4] [Reference Citation Analysis]
351 Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016;128:2599-606. [PMID: 27737890 DOI: 10.1182/blood-2016-09-692954] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 14.0] [Reference Citation Analysis]
352 Tomasson MH, Ali M, De Oliveira V, Xiao Q, Jethava Y, Zhan F, Fitzsimmons AM, Bates ML. Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. Int J Mol Sci 2018;19:E3621. [PMID: 30453544 DOI: 10.3390/ijms19113621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
353 Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, Zhu M, Zhou J, Jin S, Yao W, Yao Y, Chen G, Chang H, Zhu X, Yu L, Wu D, Fu C. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Cancer Med 2021;10:563-74. [PMID: 33356013 DOI: 10.1002/cam4.3624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
354 Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P, Dussol B, Burtey S, Gondouin B. Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016;6:e409. [PMID: 27015286 DOI: 10.1038/bcj.2016.17] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
355 Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. Amyloid 2016;23:254-9. [PMID: 27879147 DOI: 10.1080/13506129.2016.1258356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
356 Demyanets S, Kaider A, Simonitsch-Klupp I, Bayer G, Subasic A, Thalhammer R, Esterbauer H, Krauth MT, Agis H, Reiter T, Schwarzinger I. Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. Ann Hematol 2020;99:2599-609. [PMID: 32935190 DOI: 10.1007/s00277-020-04249-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Tabchi S, Nair R, Kunacheewa C, Patel KK, Lee HC, Thomas SK, Amini B, Ahmed S, Mehta RS, Bashir Q, Qazilbash MH, Weber DM, Orlowski RZ, Alexanian R, Feng L, Manasanch EE. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 2019;19:560-9. [PMID: 31201134 DOI: 10.1016/j.clml.2019.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
358 Cooke RE, Quinn KM, Quach H, Harrison S, Prince HM, Koldej R, Ritchie D. Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. Front Immunol 2020;11:2153. [PMID: 33013907 DOI: 10.3389/fimmu.2020.02153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
359 Liu XL, Bai J, Fan HQ, Yang YP, Yue TT, Zhang Y, Yang PY, Gao SJ, Li W, Jin FY. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities]. Zhonghua Xue Ye Xue Za Zhi 2019;40:644-9. [PMID: 31495130 DOI: 10.3760/cma.j.issn.0253-2727.2019.08.004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
360 Kraj M, Kruk B, Endean K, Warzocha K, Budziszewska K, Dąbrowska M. Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland. Case Rep Hematol 2015;2015:809840. [PMID: 26881153 DOI: 10.1155/2015/809840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
361 Li J, Bao L, Xia Z, Wang S, Zhou X, Ding K, Zhang W, Yang W, Li B, Fu C, Chen B, Hua L, Wang L, Luo J, Yang Y, Xu T, Wang W, Huang Y, Wu G, Liu P. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Ann Hematol 2020;99:2589-98. [PMID: 32892275 DOI: 10.1007/s00277-020-04234-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
362 Vaxman I, Visram A, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Berger T, Gertz MA. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. Bone Marrow Transplant 2021;56:1144-50. [PMID: 33273658 DOI: 10.1038/s41409-020-01159-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
363 Salomon-Perzyński A, Jamroziak K, Głodkowska-Mrówka E. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications. Diagnostics (Basel) 2021;11:1534. [PMID: 34573876 DOI: 10.3390/diagnostics11091534] [Reference Citation Analysis]
364 Bordini J, Morisi F, Cerruti F, Cascio P, Camaschella C, Ghia P, Campanella A. Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies. Cancers (Basel) 2020;12:E970. [PMID: 32295216 DOI: 10.3390/cancers12040970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
365 Abe Y, Kobayashi T, Usui Y, Narita K, Kobayashi H, Kitadate A, Miura D, Takeuchi M, Matsue K. N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma. Oncotarget 2019;10:1160-70. [PMID: 30800225 DOI: 10.18632/oncotarget.26647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
366 Park YM. Imaging Findings of Plasmacytoma of Both Breasts as a Preceding Manifestation of Multiple Myeloma. Case Rep Med 2016;2016:6595610. [PMID: 26925106 DOI: 10.1155/2016/6595610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
367 Vasilevskiy L, Akhondi H, Wierman A. POEMS syndrome complicated by ischaemic stroke and cerebral vasculitis. BMJ Case Rep 2019;12:e229428. [PMID: 31302621 DOI: 10.1136/bcr-2019-229428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Suntharalingam S, Mikat C, Wetter A, Guberina N, Salem A, Heil P, Forsting M, Nassenstein K. Whole-body ultra-low dose CT using spectral shaping for detection of osteolytic lesion in multiple myeloma. Eur Radiol 2018;28:2273-80. [PMID: 29322333 DOI: 10.1007/s00330-017-5243-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
369 Lisch W, Vossmerbaeumer U. Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy. Am J Ophthalmol Case Rep 2020;20:100926. [PMID: 33015407 DOI: 10.1016/j.ajoc.2020.100926] [Reference Citation Analysis]
370 Barley K, Chari A. Diagnostic Advances in Multiple Myeloma. Curr Hematol Malig Rep 2016;11:111-7. [PMID: 26922745 DOI: 10.1007/s11899-016-0314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
371 Jiang D, Zhang K, Zhu Y, Zhu Y, Zou L, Hu J, Cui Y, Zhou W, Chen F, He Y. Chidamide-Induced Accumulation of Reactive Oxygen Species Increases Lenalidomide Sensitivity Against Multiple Myeloma Cells. Onco Targets Ther 2021;14:4061-75. [PMID: 34262292 DOI: 10.2147/OTT.S312249] [Reference Citation Analysis]
372 Ryu D, Kim HJ, Joung JG, Lee HO, Bae JS, Kim SJ, Kim H, Park WY, Kim K. Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. Oncotarget 2016;7:47127-33. [PMID: 27223072 DOI: 10.18632/oncotarget.9478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
373 Schieferdecker A, Hörber S, Ums M, Besemer B, Bokemeyer C, Peter A, Weisel K. Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. Blood Cancer J 2020;10:2. [PMID: 31915365 DOI: 10.1038/s41408-019-0267-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
374 Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 2018;103:336-43. [PMID: 29217779 DOI: 10.3324/haematol.2017.176073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
375 Baldi D, Tramontano L, Alfano V, Punzo B, Cavaliere C, Salvatore M. Whole Body Low Dose Computed Tomography Using Third-Generation Dual-Source Multidetector With Spectral Shaping: Protocol Optimization and Literature Review. Dose Response 2020;18:1559325820973131. [PMID: 33456411 DOI: 10.1177/1559325820973131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
376 Robak P, Jarych D, Mikulski D, Dróżdż I, Węgłowska E, Kotkowska A, Misiewicz M, Smolewski P, Stawiski K, Fendler W, Szemraj J, Robak T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers (Basel) 2021;13:951. [PMID: 33668794 DOI: 10.3390/cancers13050951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Visram A, Soof C, Rajkumar SV, Kumar SK, Bujarski S, Spektor TM, Kyle RA, Berenson JR, Dispenzieri A. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J 2021;11:120. [PMID: 34168119 DOI: 10.1038/s41408-021-00505-4] [Reference Citation Analysis]
378 Alawadhi A, Leb L. Massive Retroperitoneal Hemorrhage as an Initial Presentation of a Rare and Aggressive Form of Multiple Myeloma. Case Rep Hematol 2016;2016:8206826. [PMID: 26885415 DOI: 10.1155/2016/8206826] [Reference Citation Analysis]
379 Mian HS, Wildes TM. Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults? Drugs Aging 2018;35:289-302. [PMID: 29557059 DOI: 10.1007/s40266-018-0539-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
380 Withofs N, Cousin F, De Prijck B, Bonnet C, Hustinx R, Gambhir SS, Beguin Y, Caers J. A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma. Contrast Media Mol Imaging 2017;2017:6162845. [PMID: 29097930 DOI: 10.1155/2017/6162845] [Reference Citation Analysis]
381 Jiang F, Liu H, Peng F, Liu Z, Ding K, Song J, Li L, Chen J, Shao Q, Yan S, De Veirman K, Vanderkerken K, Fu R. Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma. Cancer Biol Med 2021:j. [PMID: 33960177 DOI: 10.20892/j.issn.2095-3941.2020.0430] [Reference Citation Analysis]
382 Treglia G, Bertagna F, Albano D. The "Undetermined Significance" of 18F-FDG PET/CT or PET/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS). Medicina (Kaunas) 2021;57:856. [PMID: 34441062 DOI: 10.3390/medicina57080856] [Reference Citation Analysis]
383 Palma BD, Guasco D, Pedrazzoni M, Bolzoni M, Accardi F, Costa F, Sammarelli G, Craviotto L, De Filippo M, Ruffini L, Omedè P, Ria R, Aversa F, Giuliani N. Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. Leukemia 2016;30:409-16. [PMID: 26419509 DOI: 10.1038/leu.2015.259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
384 Sachpekidis C, Kopp-Schneider A, Merz M, Jauch A, Raab MS, Goldschmidt H, Dimitrakopoulou-Strauss A. Can 18F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma? Cancers (Basel) 2020;12:E1335. [PMID: 32456181 DOI: 10.3390/cancers12051335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Aslam N, Trautman CL, Sher T. Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. Transplant Direct 2021;7:e723. [PMID: 34263021 DOI: 10.1097/TXD.0000000000001176] [Reference Citation Analysis]
386 Finkel KW, Cohen EP, Shirali A, Abudayyeh A; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clin J Am Soc Nephrol 2016;11:2273-9. [PMID: 27526708 DOI: 10.2215/CJN.01640216] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
387 Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules 2019;25:E134. [PMID: 31905752 DOI: 10.3390/molecules25010134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
388 Liu WN, Chang CF, Chung CH, Chien WC, Huang TC, Wu YY, Ho CL, Chen JH. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. PLoS One 2019;14:e0222522. [PMID: 31527921 DOI: 10.1371/journal.pone.0222522] [Reference Citation Analysis]
389 Faiman B, Valent J. Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. Blood Lymphat Cancer 2016;6:21-35. [PMID: 31360078 DOI: 10.2147/BLCTT.S90764] [Reference Citation Analysis]
390 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers (Basel) 2020;12:E2537. [PMID: 32906608 DOI: 10.3390/cancers12092537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
391 Willenbacher E, Balog A, Willenbacher W. Short overview on the current standard of treatment in newly diagnosed multiple myeloma. Memo 2018;11:59-64. [PMID: 29606980 DOI: 10.1007/s12254-018-0383-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
392 Dutta AK, Hewett DR, Fink JL, Zannettino ACW. Using genomics to better define high-risk MGUS/SMM patients. Oncotarget 2018;9:36549-50. [PMID: 30564295 DOI: 10.18632/oncotarget.26390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
393 Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, Gu LF, Wang JL, Yang N, Zhang R, Zhang H, Shen Y, Bai J, Xu Y, Wang XG, Zhang RL, Wei LL, Li ZF, Li ZZ, Geng Y, He Q, Zhuang QC, Fan XH, He AL, Zhang WG. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 2018;11:141. [PMID: 30572922 DOI: 10.1186/s13045-018-0681-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 186] [Article Influence: 61.0] [Reference Citation Analysis]
394 Caers J, Fernández de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastritis E, Minnema M, Jurczyszyn A, Beguin Y, Wäsch R, Palumbo A, Dimopoulos M, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016;21:333-42. [PMID: 26921288 DOI: 10.1634/theoncologist.2015-0303] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
395 Shen Y, Feng Y, Li F, Jia Y, Peng Y, Zhao W, Hu J, He A. lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma. Int J Oncol 2021;58:5. [PMID: 33649796 DOI: 10.3892/ijo.2021.5185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
396 Spaan I, Raymakers RA, van de Stolpe A, Peperzak V. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. J Hematol Oncol 2018;11:67. [PMID: 29776381 DOI: 10.1186/s13045-018-0615-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
397 Andronesi AG, Tanase AD, Sorohan BM, Craciun OG, Stefan L, Varady Z, Lipan L, Obrisca B, Truica A, Ismail G. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. Cancer Med 2019;8:3278-85. [PMID: 31016881 DOI: 10.1002/cam4.2187] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
398 Thomas AE, Kurup S, Jose R, Soman C. Facial Swelling as a Primary Manifestation of Multiple Myeloma. Case Rep Dent 2015;2015:319231. [PMID: 26229694 DOI: 10.1155/2015/319231] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
399 Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, Dimopoulos MA. Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. Hemasphere 2019;3:e300. [PMID: 31976475 DOI: 10.1097/HS9.0000000000000300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
400 Khade P, Devarakonda S. Coexisting multiple myeloma, lymphoma, and non-small cell lung cancer: a case report and review of the literature. Int Med Case Rep J 2017;10:373-6. [PMID: 29184450 DOI: 10.2147/IMCRJ.S147266] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
401 Owoyemi I, Sethi S, Leung N. Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case. Kidney Med 2021;3:303-6. [PMID: 33851128 DOI: 10.1016/j.xkme.2020.10.013] [Reference Citation Analysis]
402 Huang BH, Li J. [Advances in the diagnosis and treatment of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2018;39:605-8. [PMID: 30122026 DOI: 10.3760/cma.j.issn.0253-2727.2018.07.018] [Reference Citation Analysis]
403 Xiao LI, Lin F, Xiao R, Hu C, Deng M, Li D, She X, Liu F, Sun L. Multiple myeloma-associated skin light chain amyloidosis: A case of misdiagnosis. Oncol Lett 2016;11:3617-20. [PMID: 27284363 DOI: 10.3892/ol.2016.4432] [Reference Citation Analysis]
404 Blum A, Bazou D, O'Gorman P. Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. Blood Lymphat Cancer 2018;8:21-31. [PMID: 31360091 DOI: 10.2147/BLCTT.S136447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
405 Takayasu V, Laborda LS, Bernardelli R, Pinesi HT, Silva MP, Chiavelli V, Simões AB, Felipe-Silva A. Amyloidosis: an unusual cause of portal hypertension. Autops Case Rep 2016;6:9-18. [PMID: 27547738 DOI: 10.4322/acr.2016.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
406 Lionetti M, Da Vià MC, Albano F, Neri A, Bolli N, Musto P. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? Cancers (Basel) 2021;13:3319. [PMID: 34282760 DOI: 10.3390/cancers13133319] [Reference Citation Analysis]
407 Tate CJ, Mollee PN, Miles KA. Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis. BJR Open 2019;1:20180020. [PMID: 33178915 DOI: 10.1259/bjro.20180020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
408 Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Herzog W, Hillengass J. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. Blood Cancer J 2019;9:9. [PMID: 30664623 DOI: 10.1038/s41408-019-0172-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
409 Kaufman JL. Roundtable: How I treat a newly diagnosed patient with high-risk myeloma. Hematology Am Soc Hematol Educ Program 2019;2019:120-4. [PMID: 31808841 DOI: 10.1182/hematology.2019000015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
410 Liu XL, Yang YP, Bai J, Yue TT, Yang PY, Zhang Y, Fan HQ, Li W, Jin FY. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:912-7. [PMID: 31856439 DOI: 10.3760/cma.j.issn.0253-2727.2019.11.005] [Reference Citation Analysis]
411 Wongrakpanich S, George G, Chaiwatcharayut W, Biso S, Candelario N, Mittal V, Pomerantz S, Varadi G. The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma. J Clin Lab Anal 2016;30:1208-13. [PMID: 27239981 DOI: 10.1002/jcla.22004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
412 Simeone FJ, Harvey JP, Yee AJ, O'Donnell EK, Raje NS, Torriani M, Bredella MA. Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. Skeletal Radiol 2019;48:773-9. [PMID: 30218303 DOI: 10.1007/s00256-018-3066-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
413 Mai EK, Hielscher T, Kloth JK, Merz M, Shah S, Raab MS, Hillengass M, Wagner B, Jauch A, Hose D, Weber MA, Delorme S, Goldschmidt H, Hillengass J. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. Haematologica 2015;100:818-25. [PMID: 25795721 DOI: 10.3324/haematol.2015.124115] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
414 Tadmor T, Levy I, Vadasz Z. Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell Dyscrasias. Turk J Haematol 2018;35:116-21. [PMID: 29589834 DOI: 10.4274/tjh.2018.0022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
415 Rustad EH, Hultcrantz M, Yellapantula VD, Akhlaghi T, Ho C, Arcila ME, Roshal M, Patel A, Chen D, Devlin SM, Jacobsen A, Huang Y, Miller JE, Papaemmanuil E, Landgren O. Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS One 2019;14:e0211600. [PMID: 30901326 DOI: 10.1371/journal.pone.0211600] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
416 Vuckovic S, Bryant CE, Lau KHA, Yang S, Favaloro J, McGuire HM, Clark G, de St Groth BF, Marsh-Wakefield F, Nassif N, Abadir E, Vanguru V, McCulloch D, Brown C, Larsen S, Dunkley S, Khoo L, Gibson J, Boyle R, Joshua D, Ho PJ. Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients. Blood Adv 2020;4:4593-604. [PMID: 32986791 DOI: 10.1182/bloodadvances.2020002237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
417 Wichert S, Juliusson G, Johansson Å, Sonesson E, Teige I, Wickenberg AT, Frendeus B, Korsgren M, Hansson M. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS One 2017;12:e0171205. [PMID: 28158311 DOI: 10.1371/journal.pone.0171205] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
418 Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, Boyle E, Chretien ML, Fontan J, Belhadj K, Brechignac S, Decaux O, Voillat L, Rodon P, Fitoussi O, Araujo C, Benboubker L, Fontan C, Tiab M, Godmer P, Luycx O, Allangba O, Pignon JM, Fuzibet JG, Legros L, Stoppa AM, Dib M, Pegourie B, Orsini-Piocelle F, Karlin L, Arnulf B, Roussel M, Garderet L, Mohty M, Meuleman N, Doyen C, Lenain P, Macro M, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood 2016;128:2941-8. [PMID: 27729323 DOI: 10.1182/blood-2016-07-726778] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
419 Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep 2020;12:8951. [PMID: 33042502 DOI: 10.4081/hr.2020.8951] [Reference Citation Analysis]
420 Lee N, Moon SY, Lee JH, Park HK, Kong SY, Bang SM, Lee JH, Yoon SS, Lee DS. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. Blood Cancer J 2017;7:e530. [PMID: 28211888 DOI: 10.1038/bcj.2017.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
421 Marchica V, Franceschi V, Vescovini R, Storti P, Vicario E, Toscani D, Zorzoli A, Airoldi I, Dalla Palma B, Campanini N, Martella E, Mancini C, Costa F, Donofrio G, Giuliani N. Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy. J Hematol Oncol 2020;13:89. [PMID: 32653014 DOI: 10.1186/s13045-020-00919-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
422 Vaxman I, Al Saleh AS, Kumar S, Nitin M, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Hobbs M, Fonder A, Hwa L, Visram A, Kapoor P, Siddiqui M, Lust J, Kyle R, Rajkumar V, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz MA. Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. Cancer Med 2020;9:8895-901. [PMID: 33022868 DOI: 10.1002/cam4.3507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S. Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. Hematol Rep 2017;9:6887. [PMID: 28286629 DOI: 10.4081/hr.2017.6887] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
424 Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020;136:936-45. [PMID: 32325490 DOI: 10.1182/blood.2020005288] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 117.0] [Reference Citation Analysis]
425 Akizuki K, Matsuoka H, Toyama T, Kamiunten A, Sekine M, Shide K, Kameda T, Kawano N, Maeda K, Takeuchi M, Kawano H, Sato S, Ishizaki J, Tahira Y, Shimoda H, Hidaka T, Yamashita K, Kubuki Y, Shimoda K. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan. J Clin Med 2020;10:E105. [PMID: 33396800 DOI: 10.3390/jcm10010105] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
426 Voorhees PM, Rodriguez C, Reeves B, Nathwani N, Costa LJ, Lutska Y, Bobba P, Hoehn D, Pei H, Ukropec J, Qi M, Lin TS, Richardson PG. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv 2021;5:1092-6. [PMID: 33606004 DOI: 10.1182/bloodadvances.2020003642] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tageja N, Mailankody S, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Usmani SZ, Choyke PL, Kurdziel K, Landgren O. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. Leuk Lymphoma 2016;57:1114-21. [PMID: 26690712 DOI: 10.3109/10428194.2015.1090572] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
428 Lecouvet FE, Boyadzhiev D, Collette L, Berckmans M, Michoux N, Triqueneaux P, Pasoglou V, Jamar F, Vekemans MC. MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. Eur Radiol 2020;30:1927-37. [PMID: 31844960 DOI: 10.1007/s00330-019-06469-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
429 Mateos MV, González-Calle V. Timing of treatment of smoldering myeloma: early treatment. Blood Adv 2018;2:3045-9. [PMID: 30425068 DOI: 10.1182/bloodadvances.2018021220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
430 Hinge M, Andersen KT, Lund T, Jørgensen HB, Holdgaard PC, Ormstrup TE, Østergaard LL, Plesner T. Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients. Haematologica 2016;101:e415-8. [PMID: 27390357 DOI: 10.3324/haematol.2016.146092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
431 Mehdi SH, Nafees S, Mehdi SJ, Morris CA, Mashouri L, Yoon D. Animal Models of Multiple Myeloma Bone Disease. Front Genet 2021;12:640954. [PMID: 34163520 DOI: 10.3389/fgene.2021.640954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Narita K, Kobayashi H, Abe Y, Kitadate H, Takeuchi M, Matsue K. Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma. Int J Hematol 2018;108:371-4. [PMID: 29978432 DOI: 10.1007/s12185-018-2489-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
433 Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 2020;95:672-90. [PMID: 32086970 DOI: 10.1002/ajh.25764] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
434 Papadimitriou K, Kostopoulos IV, Tsopanidou A, Orologas-Stavrou N, Kastritis E, Tsitsilonis O, Dimopoulos MA, Terpos E. Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. Cancers (Basel) 2020;12:E2006. [PMID: 32707884 DOI: 10.3390/cancers12082006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
435 Maes A, Menu E, Veirman K, Maes K, Vand Erkerken K, De Bruyne E. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget 2017;8:90501-20. [PMID: 29163849 DOI: 10.18632/oncotarget.18765] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
436 Baertsch MA, Goldschmidt H. [Multiple myeloma : What has been confirmed in therapy?]. Internist (Berl) 2017;58:1250-7. [PMID: 29098319 DOI: 10.1007/s00108-017-0337-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
437 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
438 Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network. Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2015;13:1398-435. [PMID: 26553768 DOI: 10.6004/jnccn.2015.0167] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 8.6] [Reference Citation Analysis]
439 Mateos MV, Landgren O. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Cancer Treat Res 2016;169:3-12. [PMID: 27696254 DOI: 10.1007/978-3-319-40320-5_1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
440 Surgeon’s Committee of the Chinese Myeloma Working Group of the International Myeloma Foundation. Consensus on Surgical Management of Myeloma Bone Disease.Orthop Surg. 2016;8:263-269. [PMID: 27627707 DOI: 10.1111/os.12267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
441 Wildes TM, Campagnaro E. Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. J Geriatr Oncol 2017;8:1-7. [PMID: 27118356 DOI: 10.1016/j.jgo.2016.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
442 Dhakal B, Girnius S, Hari P. Recent advances in understanding multiple myeloma. F1000Res 2016;5:F1000 Faculty Rev-2053. [PMID: 27610224 DOI: 10.12688/f1000research.8777.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
443 Friend N, Noll JE, Opperman KS, Clark KC, Mrozik KM, Vandyke K, Hewett DR, Zannettino ACW. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS One 2020;15:e0228408. [PMID: 31995627 DOI: 10.1371/journal.pone.0228408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
444 Sun M, Cheng J, Ren C, Zhang Y, Li Y, Li Y, Zhang S. Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers. Quant Imaging Med Surg 2021;11:3767-80. [PMID: 34341748 DOI: 10.21037/qims-20-1361] [Reference Citation Analysis]
445 Krebs S, Ganly I, Ghossein R, Yang J, Yahalom J, Schöder H. Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage-Case Report. Front Oncol 2017;7:284. [PMID: 29230383 DOI: 10.3389/fonc.2017.00284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
446 Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, Bowles N, Nathwani N, Rosenzweig M, Sahebi F, Karanes C, Simpson J, Sanchez JF, Yamauchi D, Parayno M, Chowdhury A, Caserta E, Marcucci G, Rockne R, Wu AM, Wong J, Forman SJ, Colcher D, Yazaki P, Shively J, Pichiorri F. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv 2020;4:5194-202. [PMID: 33095874 DOI: 10.1182/bloodadvances.2020002603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
447 Arahata M, Shimadoi S, Yamatani S, Hayashi S, Miwa S, Asakura H, Nakao S. Three cases of systemic amyloidosis successfully diagnosed by subcutaneous fat tissue biopsy of the hip. Clin Interv Aging 2016;11:1061-6. [PMID: 27540285 DOI: 10.2147/CIA.S110636] [Reference Citation Analysis]
448 Abughanimeh O, Qasrawi A, Abu Omar M, Bahaj W, Abu Ghanimeh M. A Case of Multiple Myeloma Associated with Extramedullary Plasmacytoma of the Gallbladder Manifesting as Acute Cholecystitis. Cureus 2018;10:e2688. [PMID: 30050743 DOI: 10.7759/cureus.2688] [Reference Citation Analysis]
449 Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9-16. [PMID: 25931582 DOI: 10.1182/blood-2015-03-631747] [Cited by in Crossref: 858] [Cited by in F6Publishing: 788] [Article Influence: 143.0] [Reference Citation Analysis]
450 Sarfraz H, Anand K, Liu S, Shah S. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancermedicalscience 2020;14:1012. [PMID: 32256695 DOI: 10.3332/ecancer.2020.1012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers (Basel) 2021;13:2712. [PMID: 34072645 DOI: 10.3390/cancers13112712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
452 Curado MP, Oliveira MM, Silva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med 2018;7:2101-8. [PMID: 29573332 DOI: 10.1002/cam4.1347] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
453 Sabatino R, Perrone A, Cuomo M, Liotti S, Barchiesi V, Cantile M, Cavalcanti E. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. Int J Mol Sci 2017;18:E804. [PMID: 28417905 DOI: 10.3390/ijms18040804] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
454 Sabobeh T, Brugioni EK, Masoud A, Madhusudhana S, Mateescu V. A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma. Cureus 2021;13:e13293. [PMID: 33728224 DOI: 10.7759/cureus.13293] [Reference Citation Analysis]
455 Yu CY, Xiang S, Huang Z, Johnson TS, Zhan X, Han Z, Abu Zaid M, Huang K. Gene Co-expression Network and Copy Number Variation Analyses Identify Transcription Factors Associated With Multiple Myeloma Progression. Front Genet 2019;10:468. [PMID: 31156714 DOI: 10.3389/fgene.2019.00468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
456 Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R, Sánchez MJ. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol 2021;23:1429-39. [PMID: 33433836 DOI: 10.1007/s12094-020-02541-1] [Reference Citation Analysis]
457 Ali M, Ajore R, Wihlborg AK, Niroula A, Swaminathan B, Johnsson E, Stephens OW, Morgan G, Meissner T, Turesson I, Goldschmidt H, Mellqvist UH, Gullberg U, Hansson M, Hemminki K, Nahi H, Waage A, Weinhold N, Nilsson B. The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. Nat Commun 2018;9:1649. [PMID: 29695719 DOI: 10.1038/s41467-018-04082-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
458 Treitl KM, Ricke J, Baur-Melnyk A. Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging. Skeletal Radiol 2021. [PMID: 34031705 DOI: 10.1007/s00256-021-03799-4] [Reference Citation Analysis]
459 Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA. Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. Leukemia 2019;33:313-8. [PMID: 30573778 DOI: 10.1038/s41375-018-0339-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
460 Yogo T, Okazuka K, Nashimoto J, Uto Y, Sato K, Miyazaki K, Ogura M, Yoshiki Y, Abe Y, Tsukada N, Ishida T, Suzuki K. Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. Int J Hematol 2019;110:431-7. [PMID: 31236823 DOI: 10.1007/s12185-019-02692-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
461 Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget 2018;9:25254-64. [PMID: 29861868 DOI: 10.18632/oncotarget.25402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
462 Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD Jr, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol 2018;180:821-30. [PMID: 29435979 DOI: 10.1111/bjh.15058] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
463 Rajan AM, Buadi FK, Rajkumar V. Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. Am J Hematol 2016;91:E5-6. [PMID: 26572926 DOI: 10.1002/ajh.24244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
464 Moreau C, Lefevre CR, Decaux O. How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology? Ann Transl Med 2020;8:973. [PMID: 32953773 DOI: 10.21037/atm.2020.03.200] [Reference Citation Analysis]
465 Kuwabara C, Sakuma Y, Kume A, Tamura Y, Shimizu R, Iwai R, Ishii A, Tanaka H. Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study. Int J Hematol 2019;109:154-61. [PMID: 30406907 DOI: 10.1007/s12185-018-2555-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
466 Zheleznyak A, Shokeen M, Achilefu S. Nanotherapeutics for multiple myeloma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10:e1526. [PMID: 29701006 DOI: 10.1002/wnan.1526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
467 Phinyo P, Maihom T, Phanphaisarn A, Kerdsinchai P, Rattarittamrong E, Patumanond J, Pruksakorn D. Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx). BMC Fam Pract 2020;21:215. [PMID: 33087068 DOI: 10.1186/s12875-020-01283-x] [Reference Citation Analysis]
468 Wang C, Soekojo CY, Mel S, Ooi M, Chen Y, Goh AZK, Nagarajan C, Chng WJ. Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Cancers (Basel) 2020;12:E1759. [PMID: 32630644 DOI: 10.3390/cancers12071759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Ames J, Al-Samaraee A, Takahashi T. Extraosseous Multiple Myeloma: Case Report of Presentation in the Lower Extremity Soft Tissues with Literature Review. Case Rep Radiol 2017;2017:9159035. [PMID: 29391963 DOI: 10.1155/2017/9159035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
470 Bailly C, Gouard S, Lacombe M, Remaud-Le Saëc P, Chalopin B, Bourgeois M, Chouin N, Tripier R, Halime Z, Haddad F, Faivre-Chauvet A, Kraeber-Bodéré F, Chérel M, Bodet-Milin C. Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. Oncotarget 2018;9:9061-72. [PMID: 29507674 DOI: 10.18632/oncotarget.23886] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
471 Takamatsu H, Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K. Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. Int J Hematol 2019;109:377-81. [PMID: 30778767 DOI: 10.1007/s12185-019-02615-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
472 Hu X, Wang W, Wang Y, Liu K. Fear of cancer recurrence in patients with multiple myeloma: Prevalence and predictors based on a family model analysis. Psychooncology 2021;30:176-84. [PMID: 32931646 DOI: 10.1002/pon.5546] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
473 Vaxman I, Muchtar E, Jacob E, Kapoor P, Kumar S, Dispenzieri A, Buadi F, Dingli D, Gonsalves W, Kourelis T, Warsame R, Lacy M, Hogan W, Gertz MA. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplant Cell Ther 2021;27:770.e1-7. [PMID: 34153504 DOI: 10.1016/j.jtct.2021.06.016] [Reference Citation Analysis]
474 Bosseboeuf A, Seillier C, Mennesson N, Allain-Maillet S, Fourny M, Tallet A, Piver E, Lehours P, Mégraud F, Berthelot L, Harb J, Bigot-Corbel E, Hermouet S. Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. Front Immunol 2020;11:854. [PMID: 32536913 DOI: 10.3389/fimmu.2020.00854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
475 Mei H, Xiang Y, Mei H, Fang B, Wang Q, Cao D, Hu Y, Guo T. Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells. Int J Mol Med 2018;42:2676-88. [PMID: 30226553 DOI: 10.3892/ijmm.2018.3857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
476 Gupta S, Karandikar NJ, Ginader T, Bellizzi AM, Holman CJ. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters. Cytometry B Clin Cytom 2018;94:500-8. [PMID: 29316245 DOI: 10.1002/cyto.b.21624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
477 Chalopin T, Barillot I, Biny JP, Arbion F, Besson M, Santiago-Ribeiro M, Piver E, Herault O, Gyan E, Benboubker L. Primary solitary plasmacytoma of the liver - successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report. J Med Case Rep 2017;11:193. [PMID: 28716071 DOI: 10.1186/s13256-017-1358-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
478 Duclos V, Iep A, Gomez L, Goldfarb L, Besson FL. PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. Int J Mol Sci 2021;22:4159. [PMID: 33923839 DOI: 10.3390/ijms22084159] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
479 Innao V, Allegra A, Ginaldi L, Pioggia G, De Martinis M, Musolino C, Gangemi S. Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies. Int J Mol Sci 2021;22:4922. [PMID: 34066482 DOI: 10.3390/ijms22094922] [Reference Citation Analysis]
480 Wang J, Zhang LN, Shi QL, Qu XY, Chen LJ, Li JY, Zhang R. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease]. Zhonghua Xue Ye Xue Za Zhi 2020;41:822-8. [PMID: 33190439 DOI: 10.3760/cma.j.issn.0253-2727.2020.10.006] [Reference Citation Analysis]
481 Ríos-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, de la Guardia AMDVD, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Des Devel Ther 2017;11:2399-408. [PMID: 28860711 DOI: 10.2147/DDDT.S115456] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
482 Singh G. Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio. J Clin Med Res 2017;9:46-57. [PMID: 27924175 DOI: 10.14740/jocmr2802w] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
483 Thumallapally N, Yu H, Asti D, Vennepureddy A, Terjanian T. Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther 2016;9:4843-58. [PMID: 27540299 DOI: 10.2147/OTT.S110189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
484 Ryu JH, Zimolzak AJ. Natural Language Processing of Serum Protein Electrophoresis Reports in the Veterans Affairs Health Care System. JCO Clin Cancer Inform 2020;4:749-56. [PMID: 32813561 DOI: 10.1200/CCI.19.00167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Wang Z, Yuan Y, Zhang L, Min Z, Zhou D, Yu S, Wang P, Ju S, Jun L, Fu J. Impact of cell fusion in myeloma marrow microenvironment on tumor progression. Oncotarget 2018;9:30997-1006. [PMID: 30123422 DOI: 10.18632/oncotarget.25742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
486 Singh S, Kumar A, Bhaisora KS, Srivastava AK, Behari S. An unusual case of solitary spinal intradural plasmacytoma: The unforeseen challenge. J Craniovertebr Junction Spine 2019;10:192-6. [PMID: 31772434 DOI: 10.4103/jcvjs.JCVJS_51_19] [Reference Citation Analysis]
487 Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, Zhang X, Mendonça M, Majewski N, Nanjunda R, Chin D, Packman K, Elsayed Y, Attar R, Gaudet F. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv 2020;4:4538-49. [PMID: 32956453 DOI: 10.1182/bloodadvances.2020002393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
488 Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits. Oncotarget 2018;9:9975-91. [PMID: 29515784 DOI: 10.18632/oncotarget.24160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
489 Lindemann C, Enders P, Brinkkoetter PT, Völker LA. Crystalline deposits in the cornea and various areas of the kidney as symptoms of an underlying monoclonal gammopathy: a case report. BMC Nephrol 2021;22:117. [PMID: 33823814 DOI: 10.1186/s12882-021-02309-x] [Reference Citation Analysis]
490 Abdrabou AK, Sharif FA, Fakih RE, Hashmi S, Khafaga YM, Alhayli S, Zahrani HA, Ahmed S, Fraih FA, Shaheen M, Rasheed W, Chaudhri NA, Mohareb FA, Khalil H, Aljurf M, Hanbali A. Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ann Saudi Med 2021;41:198-205. [PMID: 34420396 DOI: 10.5144/0256-4947.2021.198] [Reference Citation Analysis]
491 Fau JB, El-Cheikh R, Brillac C, Koiwai K, Mace N, Campana F, Semiond D, Nguyen L. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients. CPT Pharmacometrics Syst Pharmacol 2020;9:649-58. [PMID: 33021075 DOI: 10.1002/psp4.12561] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
492 Masri A, Bukhari S, Ahmad S, Nieves R, Eisele YS, Follansbee W, Brownell A, Wong TC, Schelbert E, Soman P. Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Cardiovasc Imaging 2020;13:e010249. [PMID: 32063053 DOI: 10.1161/CIRCIMAGING.119.010249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 14.0] [Reference Citation Analysis]
493 Özenver N, Abdelfatah S, Klinger A, Fleischer E, Efferth T. Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma. Invest New Drugs 2021;39:348-61. [PMID: 32978717 DOI: 10.1007/s10637-020-01012-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
494 Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130:974-81. [PMID: 28637662 DOI: 10.1182/blood-2017-05-785246] [Cited by in Crossref: 275] [Cited by in F6Publishing: 253] [Article Influence: 68.8] [Reference Citation Analysis]
495 Mesguich C, Latrabe V, Hulin C, Lascaux A, Bordenave L, Hindié E, Marit G. Prospective Comparison of 18-FDG PET/CT and Whole-Body MRI with Diffusion-Weighted Imaging in the Evaluation of Treatment Response of Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant. Cancers (Basel) 2021;13:1938. [PMID: 33923781 DOI: 10.3390/cancers13081938] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Ahmed N, Sriskandarajah P, Burd C, Riddell A, Boyd K, Kaiser M, Messiou C. Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. Br J Radiol 2019;92:20180822. [PMID: 30676781 DOI: 10.1259/bjr.20180822] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
497 LeBlanc R, Song K, White D, Christofides A, Doucette S. Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma. Curr Oncol 2019;26:e581-94. [PMID: 31548829 DOI: 10.3747/co.26.5565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Nobacht S, Kusters B, Breukink MB, Rongen GA, Cruysberg JRM. Recurrence of paraproteinemic crystalline keratopathy after corneal transplantation: A case of monoclonal gammopathy of ocular significance. Am J Ophthalmol Case Rep 2020;19:100803. [PMID: 32671285 DOI: 10.1016/j.ajoc.2020.100803] [Reference Citation Analysis]
499 Hofmann JN, Beane Freeman LE, Murata K, Andreotti G, Shearer JJ, Thoren K, Ramanathan L, Parks CG, Koutros S, Lerro CC, Liu D, Rothman N, Lynch CF, Graubard BI, Sandler DP, Alavanja MC, Landgren O. Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. Environ Health Perspect 2021;129:17003. [PMID: 33404262 DOI: 10.1289/EHP6960] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
500 Santockyte R, Jin C, Pratt J, Ammar R, Desai K, Bolisetty M, Das P, Popa-McKiver M, Puig O. Sensitive multiple myeloma disease monitoring by mass spectrometry. Blood Cancer J 2021;11:78. [PMID: 33927186 DOI: 10.1038/s41408-021-00473-9] [Reference Citation Analysis]
501 Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 2015;100:1254-66. [PMID: 26432383 DOI: 10.3324/haematol.2014.117176] [Cited by in Crossref: 189] [Cited by in F6Publishing: 155] [Article Influence: 37.8] [Reference Citation Analysis]
502 Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, Zhang Y, An S, Li L, Hou J, Huang G, Liu J, Zhao YJ, Wei W. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging 2021;48:2749-60. [PMID: 33543326 DOI: 10.1007/s00259-021-05218-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
503 Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol 2017;35:2900-10. [PMID: 28498784 DOI: 10.1200/JCO.2016.69.2517] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 35.3] [Reference Citation Analysis]
504 Kumar SK. Timing of treatment of smoldering myeloma: delay until progression. Blood Adv 2018;2:3050-3. [PMID: 30425069 DOI: 10.1182/bloodadvances.2018021238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
505 Chatterjee G, Gujral S, Subramanian PG, Tembhare PR. Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. Indian J Hematol Blood Transfus 2017;33:303-15. [PMID: 28824230 DOI: 10.1007/s12288-017-0822-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
506 Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood 2021;137:1905-19. [PMID: 33751108 DOI: 10.1182/blood.2020009088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
507 Wert J, Farooq A, Jalil A. Extramedullary Plasmacytoma Causing Myelopathy Resulting in Gait Imbalance. Cureus 2021;13:e15171. [PMID: 34168932 DOI: 10.7759/cureus.15171] [Reference Citation Analysis]
508 Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, Castella B, Faini AC, Massaia M, Pistoia V, Giuliani N, Malavasi F. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. Oncoimmunology 2018;7:e1458809. [PMID: 30221054 DOI: 10.1080/2162402X.2018.1458809] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
509 Geng CY, Yang GZ, Wang GR, Wang HJ, Zhou HX, Zhang ZY, Jian Y, Chen WM. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients]. Zhonghua Xue Ye Xue Za Zhi 2021;42:390-5. [PMID: 34218581 DOI: 10.3760/cma.j.issn.0253-2727.2021.05.007] [Reference Citation Analysis]
510 Federico C, Sacco A, Belotti A, Ribolla R, Cancelli V, Giacomini A, Ronca R, Chiarini M, Imberti L, Marini M, Rossi G, Presta M, Paiva B, Roccaro AM. Circulating microRNAs and Their Role in Multiple Myeloma. Noncoding RNA 2019;5:E37. [PMID: 31052608 DOI: 10.3390/ncrna5020037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
511 Deshet-Unger N, Hiram-Bab S, Haim-Ohana Y, Mittelman M, Gabet Y, Neumann D. Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. Sci Rep 2016;6:30998. [PMID: 27481313 DOI: 10.1038/srep30998] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
512 Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, Dihel M, Balcarkova J, Krhovska P, Pika T, Gajdos P, Behalek M, Vasinek M, Papajik T. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep 2021;11:14671. [PMID: 34282158 DOI: 10.1038/s41598-021-93835-z] [Reference Citation Analysis]
513 Castañeda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintrón CR, Birmann BM, Epstein MM. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. Int J Cancer 2020;146:35-43. [PMID: 30802944 DOI: 10.1002/ijc.32232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
514 Papanota AM, Karousi P, Kontos CK, Ntanasis-Stathopoulos I, Scorilas A, Terpos E. Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background. Int J Mol Sci 2021;22:2375. [PMID: 33673480 DOI: 10.3390/ijms22052375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
515 Lahuerta JJ, Paiva B, Jiménez de Ubieto A, Sánchez-Pina J, Mateos MV, Bladé J, San-Miguel JF. Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches. Blood Adv 2021;5:1340-3. [PMID: 33656540 DOI: 10.1182/bloodadvances.2020003996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 San-Miguel JF, Einsele H, Moreau P. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther 2016;33:1896-920. [PMID: 27677481 DOI: 10.1007/s12325-016-0413-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
517 Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clin Proc 2017;92:838-50. [PMID: 28473042 DOI: 10.1016/j.mayocp.2017.02.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
518 Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol 2020;6:425-32. [PMID: 31830214 DOI: 10.1001/jamaoncol.2019.4659] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
519 Dutoit JC, Verstraete KL. Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. Skeletal Radiol 2017;46:733-50. [PMID: 28289855 DOI: 10.1007/s00256-017-2609-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
520 Bosseboeuf A, Feron D, Tallet A, Rossi C, Charlier C, Garderet L, Caillot D, Moreau P, Cardó-Vila M, Pasqualini R, Arap W, Nelson AD, Wilson BS, Perreault H, Piver E, Weigel P, Girodon F, Harb J, Bigot-Corbel E, Hermouet S. Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight 2017;2:95367. [PMID: 28978808 DOI: 10.1172/jci.insight.95367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
521 Almeida TMX, Cavalcanti ÉFF, Freitas ADS, Magalhães RJP, Maiolino A, Torres SR. Can dentists detect multiple myeloma through oral manifestations? Rev Bras Hematol Hemoter 2018;40:43-9. [PMID: 29519372 DOI: 10.1016/j.bjhh.2017.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
522 Yang PY, Liu MM, Fan HQ, Yang YP, Han W, Yu XY, Yue TT, Su KJ, Guo Q, Gao SJ, Jin FY. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2019;40:584-8. [PMID: 32397022 DOI: 10.3760/cma.j.issn.0253-2727.2019.07.009] [Reference Citation Analysis]
523 Yu H, Peng S, Chen X, Han S, Luo J. Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. J Clin Lab Anal 2020;34:e23399. [PMID: 32608537 DOI: 10.1002/jcla.23399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
524 Sathick IJ, Drosou ME, Leung N. Myeloma light chain cast nephropathy, a review. J Nephrol 2019;32:189-98. [PMID: 29730782 DOI: 10.1007/s40620-018-0492-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
525 Tessier C, Allard T, Boudreault JS, Kaedbey R, Éthier V, Fortin F, Pavic M. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study. Curr Oncol 2021;28:2029-39. [PMID: 34073289 DOI: 10.3390/curroncol28030188] [Reference Citation Analysis]
526 Shires K, Wyk TV, Wienand K. The expression of multiple cancer/testis antigens can potentially be used to detect circulating disease and clonal evolution in the peripheral blood of multiple myeloma patients. Blood Res 2021;56:156-65. [PMID: 34462402 DOI: 10.5045/br.2021.2020335] [Reference Citation Analysis]
527 Ji X, Huang W, Dong H, Shen Z, Zheng M, Zou D, Shen W, Xia S. Evaluation of bone marrow infiltration in multiple myeloma using whole-body diffusion-weighted imaging and T1-weighted water-fat separation Dixon. Quant Imaging Med Surg 2021;11:641-51. [PMID: 33532264 DOI: 10.21037/qims-20-289] [Reference Citation Analysis]
528 Kahale LA, Matar CF, Tsolakian I, Hakoum MB, Yosuico VE, Terrenato I, Sperati F, Barba M, Hicks LK, Schünemann H, Akl EA. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database Syst Rev 2021;9:CD014739. [PMID: 34582035 DOI: 10.1002/14651858.CD014739] [Reference Citation Analysis]
529 Steiner N, Jöhrer K, Plewan S, Brunner-Véber A, Göbel G, Nachbaur D, Wolf D, Gunsilius E, Untergasser G. The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. Cancers (Basel) 2020;12:E2341. [PMID: 32825035 DOI: 10.3390/cancers12092341] [Reference Citation Analysis]
530 Nicholson BD, Oke JL, Rose PW, Mant D. Variation in Direct Access to Tests to Investigate Cancer: A Survey of English General Practitioners. PLoS One 2016;11:e0159725. [PMID: 27447931 DOI: 10.1371/journal.pone.0159725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
531 Vaxman I, Dispenzieri A, Muchtar E, Gertz M. New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Rev 2020;40:100636. [PMID: 31706583 DOI: 10.1016/j.blre.2019.100636] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
532 Song J, Jiang F, Liu H, Ding K, Ren Y, Li L, Wang G, Shao Z, Fu R. Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis. J Clin Lab Anal 2020;34:e23057. [PMID: 31663630 DOI: 10.1002/jcla.23057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
533 Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. Int J Mol Sci 2021;22:4462. [PMID: 33923357 DOI: 10.3390/ijms22094462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
534 Alghisi A, Borghetti P, Maddalo M, Roccaro AM, Tucci A, Mazzola R, Magrini SM, Lo Casto A, Bonù ML, Tomasini D, Pasinetti N, Peretto G, Bertagna F, Tomasi C, Buglione M, Triggiani L. Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. J Cancer Res Clin Oncol 2021;147:1773-9. [PMID: 33201300 DOI: 10.1007/s00432-020-03452-y] [Reference Citation Analysis]
535 Mitra AK, Harding T, Mukherjee UK, Jang JS, Li Y, HongZheng R, Jen J, Sonneveld P, Kumar S, Kuehl WM, Rajkumar V, Van Ness B. A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. Blood Cancer J 2017;7:e581. [PMID: 28665416 DOI: 10.1038/bcj.2017.56] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
536 Mulé S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, Nouri R, Itti E, Luciani A. Whole-Body Functional MRI and PET/MRI in Multiple Myeloma. Cancers (Basel) 2020;12:E3155. [PMID: 33121132 DOI: 10.3390/cancers12113155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
537 Solimando AG, Summa S, Vacca A, Ribatti D. Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers (Basel) 2020;12:E3380. [PMID: 33203154 DOI: 10.3390/cancers12113380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
538 McElroy S, Winfield JM, Westerland O, Charles-Edwards G, Bell J, Neji R, Stemmer A, Kiefer B, Streetly M, Goh V. Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5 T. MAGMA 2021;34:513-21. [PMID: 33355719 DOI: 10.1007/s10334-020-00898-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
539 Lu M, Wu Y, Gao W, Tian Y, Wang G, Liu A, Chen W. Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing. Front Genet 2021;12:625019. [PMID: 34108986 DOI: 10.3389/fgene.2021.625019] [Reference Citation Analysis]
540 Wong KY, Morgan GJ, Boyle EM, Cheng ASL, Yip KY, Chim CS. A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. Sci Rep 2021;11:7009. [PMID: 33772052 DOI: 10.1038/s41598-021-86473-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
541 Deng C, Si C, Ye X, Zhou Q, Zeng T, Huang Z, Huang W, Zhu P, Zhong Q, Wu Z, Zhu H, Lin Q, Zhang W, Fu L, Zheng Y, Qian T. Prognostic significance of FSCN family in multiple myeloma. J Cancer 2021;12:1936-44. [PMID: 33753991 DOI: 10.7150/jca.53675] [Reference Citation Analysis]
542 Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget 2016;7:59029-48. [PMID: 27437873 DOI: 10.18632/oncotarget.10665] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
543 Shehata AMF, Kamal Eldin SM, Osman NF, Helwa MA. Deregulated Expression of Long Non-coding RNA HOX Transcript Antisense RNA (HOTAIR) in Egyptian Patients with Multiple Myeloma. Indian J Hematol Blood Transfus 2020;36:271-6. [PMID: 32425377 DOI: 10.1007/s12288-019-01211-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
544 Grammatico S, Scalzulli E, Petrucci MT. Solitary Plasmacytoma. Mediterr J Hematol Infect Dis 2017;9:e2017052. [PMID: 28894561 DOI: 10.4084/MJHID.2017.052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
545 Varga G, Mikala G, Gopcsa L, Csukly Z, Kollai S, Balázs G, Botond T, Wohner N, Horváth L, Szombath G, Farkas P, Masszi T. Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature. J Oncol 2018;2018:3970169. [PMID: 29849629 DOI: 10.1155/2018/3970169] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
546 Gupta A, Mallick P, Sharma O, Gupta R, Duggal R. PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma. PLoS One 2018;13:e0207908. [PMID: 30540767 DOI: 10.1371/journal.pone.0207908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
547 Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 2018;182:495-503. [PMID: 29808907 DOI: 10.1111/bjh.15384] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
548 Han HX, Cao XX, Su W, Shen KN, Zhang L, Zhou DB, Li J. [Clinical characteristics and outcome of patients with type Ⅱ cryoglobulinemia]. Zhonghua Xue Ye Xue Za Zhi 2021;42:447-51. [PMID: 34384149 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.002] [Reference Citation Analysis]
549 Sonneveld P. Should minimal residual disease negativity not be the end point of myeloma therapy? Blood Adv 2017;1:522-5. [PMID: 29296971 DOI: 10.1182/bloodadvances.2017000109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
550 Wang T, Peng X, Qiao W, Xing Y, Yang J, Zhao J. The role of CT in PET/CT for assessing diffuse infiltration of bone marrow in multiple myeloma using the Durie-Salmon PLUS staging system. Mol Clin Oncol 2020;13:13-8. [PMID: 32454969 DOI: 10.3892/mco.2020.2039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Suryavanshi H, Patankar S, Dhumal S, Choudhari S. Solitary plasmacytoma of jaw bone: A case report and systematic review of fifty cases from literature. J Oral Maxillofac Pathol 2021;25:205. [PMID: 34349446 DOI: 10.4103/jomfp.JOMFP_251_20] [Reference Citation Analysis]
552 Gastelum ZN, Biggs DM, Scott A. Multiple Myeloma Presenting as Acute Renal Failure in the Absence of Other Characteristic Features. Cureus 2017;9:e1703. [PMID: 29159010 DOI: 10.7759/cureus.1703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
553 Naymagon L, Abdul-Hay M. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. J Med Case Rep 2019;13:153. [PMID: 31113466 DOI: 10.1186/s13256-019-2087-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
554 Zanwar S, Abeykoon JP, Kapoor P. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Curr Hematol Malig Rep 2019;14:70-82. [PMID: 30820879 DOI: 10.1007/s11899-019-00500-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
555 Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J 2021;11:24. [PMID: 33563895 DOI: 10.1038/s41408-021-00408-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
556 Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R. Long Non-Coding RNAs in Multiple Myeloma. Noncoding RNA 2019;5:E13. [PMID: 30682861 DOI: 10.3390/ncrna5010013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
557 Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 2017;17:13. [PMID: 28056880 DOI: 10.1186/s12885-016-3015-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
558 Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Invest New Drugs 2020;38:831-43. [PMID: 31359240 DOI: 10.1007/s10637-019-00840-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
559 Liang L, Li J, Fu H, Liu X, Liu P. Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. J Cancer 2019;10:4852-9. [PMID: 31598156 DOI: 10.7150/jca.31357] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
560 Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv 2018;2:2607-18. [PMID: 30327369 DOI: 10.1182/bloodadvances.2018023200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
561 Xu L, Wang X, Pan X, Wang X, Wang Q, Wu B, Cai J, Zhao Y, Chen L, Li W, Li J. Education level as a predictor of survival in patients with multiple myeloma. BMC Cancer 2020;20:737. [PMID: 32770980 DOI: 10.1186/s12885-020-07178-5] [Reference Citation Analysis]
562 Yuan RF, Dong YJ, Li CR, Huang WR, Zhang LM, Zhu Q, Xu L, Xu YJ, Xu Q, Gao GX, Jin FY. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study]. Zhonghua Xue Ye Xue Za Zhi 2020;41:10-5. [PMID: 32023748 DOI: 10.3760/cma.j.issn.0253-2727.2020.01.003] [Reference Citation Analysis]
563 . Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol 2018;93:981-1114. [PMID: 30400719 DOI: 10.1002/ajh.25117] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 27.7] [Reference Citation Analysis]
564 Tsai SY, Wang SY, Shiau YC, Wu YW. Extramedullary Soft Tissue Involvement and Discrepant Osseous Uptake on Tc-99m MDP and Ga-67 Citrate Scintigraphy in a Patient With Multiple Myeloma: A Case Report and Literature Review. Medicine (Baltimore) 2015;94:e995. [PMID: 26091480 DOI: 10.1097/MD.0000000000000995] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
565 Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, Mailankody S, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. Blood Adv 2017;1:2186-92. [PMID: 29296866 DOI: 10.1182/bloodadvances.2017007609] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
566 Holliday AC, Khan MI, Mazloom SE, Chavan RN, Grider DJ. Metastatic Multiple Myeloma to the Skin. Case Rep Dermatol Med 2019;2019:7930123. [PMID: 31781414 DOI: 10.1155/2019/7930123] [Reference Citation Analysis]
567 Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955-62. [PMID: 27002115 DOI: 10.1182/blood-2016-01-631200] [Cited by in Crossref: 387] [Cited by in F6Publishing: 368] [Article Influence: 77.4] [Reference Citation Analysis]
568 Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel) 2021;9:3. [PMID: 33498356 DOI: 10.3390/medsci9010003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
569 Ellington TD, Henley SJ, Wilson RJ, Wu M, Richardson LC. Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016. Cancer Med 2021;10:386-95. [PMID: 33270992 DOI: 10.1002/cam4.3444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
570 Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E. Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 2016;7:6521-37. [PMID: 26695547 DOI: 10.18632/oncotarget.6658] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
571 Ho M, Patel A, Goh CY, Moscvin M, Zhang L, Bianchi G. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Leukemia 2020;34:3111-25. [PMID: 33046818 DOI: 10.1038/s41375-020-01051-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
572 Scheckel CJ, Vincent Rajkumar S. Drug importation: limitations of current proposals and opportunities for improvement. Blood Cancer J 2021;11:132. [PMID: 34267190 DOI: 10.1038/s41408-021-00522-3] [Reference Citation Analysis]
573 Anderson KC. Progress and Paradigms in Multiple Myeloma. Clin Cancer Res 2016;22:5419-27. [PMID: 28151709 DOI: 10.1158/1078-0432.CCR-16-0625] [Cited by in Crossref: 84] [Cited by in F6Publishing: 56] [Article Influence: 28.0] [Reference Citation Analysis]
574 Kishimoto RK, de Freitas SL, Ratis CA, Borri D, Sitnik R, Velloso ED. Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter 2016;38:113-20. [PMID: 27208569 DOI: 10.1016/j.bjhh.2016.01.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
575 Janjetovic S, Lohneis P, Nogai A, Balci D, Rasche L, Jähne D, Bokemeyer C, Schilling G, Blau IW, Schmidt-Hieber M. Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias. Biology (Basel) 2021;10:629. [PMID: 34356484 DOI: 10.3390/biology10070629] [Reference Citation Analysis]
576 Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J 2021;11:161. [PMID: 34588423 DOI: 10.1038/s41408-021-00527-y] [Reference Citation Analysis]
577 Taş Ozyurtseven B, Serin I, Nursal AF, Pehlivan S, Pehlivan M. Medication-related osteonecrosis of the jaw (MRONJ) and eNOS Polymorphisms in multiple myeloma patients: a single center experience. BMC Oral Health 2021;21:272. [PMID: 34006261 DOI: 10.1186/s12903-021-01634-9] [Reference Citation Analysis]
578 Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, Guo T, Kou H, Liu L, Tang L, Yin P, Wang Z, Ai L, Ke S, Xia Y, Deng J, Chen L, Cai L, Sun C, Xia L, Hua G, Hu Y. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 2021;14:161. [PMID: 34627333 DOI: 10.1186/s13045-021-01170-7] [Reference Citation Analysis]
579 Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J 2021;11:50. [PMID: 33664227 DOI: 10.1038/s41408-021-00444-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
580 Kaweme NM, Changwe GJ, Zhou F. Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects. Front Med (Lausanne) 2021;8:612696. [PMID: 33718400 DOI: 10.3389/fmed.2021.612696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Derudas D, Capraro F, Martinelli G, Cerchione C. How I manage frontline transplant-ineligible multiple myeloma. Hematol Rep 2020;12:8956. [PMID: 33042505 DOI: 10.4081/hr.2020.8956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
582 Bolli N, Li Y, Sathiaseelan V, Raine K, Jones D, Ganly P, Cocito F, Bignell G, Chapman MA, Sperling AS, Anderson KC, Avet-Loiseau H, Minvielle S, Campbell PJ, Munshi NC. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 2016;6:e467. [PMID: 27588520 DOI: 10.1038/bcj.2016.72] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
583 Baa AK, Chellapuram SK, Sharma A, Malik PS, Sahoo RK, Biswas A, Thulkar S, Arun Raj ST, Kumar R, Malik S, Kumar L; for AIIMS Myeloma Group. Poems syndrome: consolidation with autologous stem cell transplantation. Bone Marrow Transplant 2021. [PMID: 34226668 DOI: 10.1038/s41409-021-01395-7] [Reference Citation Analysis]
584 Storti P, Agnelli L, Palma BD, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N. The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. Haematologica 2019;104:e465-9. [PMID: 30846495 DOI: 10.3324/haematol.2018.209999] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
585 Nayak BS, Ojar-Taylor N, St John S, Swann S, Thom J, Thomas B, Thomas L, Townsend D, Trotman S. Significance of Serum Protein Electrophoresis in the Detection of Multiple Myeloma: A Diagnostic Interpretation of Patients with Varied Immunoglobulins. Int J Prev Med 2021;12:37. [PMID: 34249286 DOI: 10.4103/ijpvm.IJPVM_222_18] [Reference Citation Analysis]
586 Legarda MA, Cejalvo MJ, de la Rubia J. Recent Advances in the Treatment of Patients with Multiple Myeloma. Cancers (Basel) 2020;12:E3576. [PMID: 33265952 DOI: 10.3390/cancers12123576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
587 Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B. Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica 2015;100:1214-21. [PMID: 26022710 DOI: 10.3324/haematol.2015.124651] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
588 Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G, Zhang CZ, Guo G, Meyerson M, Yee AJ, Boehm JS, Raje N, Golub TR. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med 2016;8:363ra147. [PMID: 27807282 DOI: 10.1126/scitranslmed.aac7037] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 19.0] [Reference Citation Analysis]
589 van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev 2016;270:95-112. [PMID: 26864107 DOI: 10.1111/imr.12389] [Cited by in Crossref: 181] [Cited by in F6Publishing: 170] [Article Influence: 36.2] [Reference Citation Analysis]
590 Tian MR, Yang PY, Yue TT, Li MY, Zhang YJ, Zhang MX, Zhang LM, Yan YR, Hu ZL, Du YZ, Li YY, Jin FY. [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:666-72. [PMID: 34547873 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.009] [Reference Citation Analysis]
591 Saltarella I, Frassanito MA, Lamanuzzi A, Brevi A, Leone P, Desantis V, Di Marzo L, Bellone M, Derudas D, Ribatti D, Chiaramonte R, Palano MT, Neri A, Mariggiò MA, Fumarulo R, Dammacco F, Racanelli V, Vacca A, Ria R. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target? Neoplasia 2019;21:93-105. [PMID: 30529074 DOI: 10.1016/j.neo.2018.10.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
592 Zhao JT, Jiang XY, Yang C, Chen M, Lan XL, Du JH, Zhou DB, Zhuang JL. [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10]. Zhonghua Xue Ye Xue Za Zhi 2021;42:295-301. [PMID: 33979973 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.005] [Reference Citation Analysis]
593 Mesguich C, Hulin C, Lascaux A, Bordenave L, Marit G, Hindié E. Choline PET/CT in Multiple Myeloma. Cancers (Basel) 2020;12:E1394. [PMID: 32481661 DOI: 10.3390/cancers12061394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
594 Ho M, Bianchi G, Anderson KC. Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev 2020;5:67-85. [PMID: 34414281 DOI: 10.1080/23808993.2020.1732205] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
595 Rajan AM, Kumar S. New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 2016;6:e451. [PMID: 27471867 DOI: 10.1038/bcj.2016.53] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
596 Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J 2019;9:32. [PMID: 30846679 DOI: 10.1038/s41408-019-0191-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
597 Offidani M, Boccadoro M, Di Raimondo F, Petrucci MT, Tosi P, Cavo M. Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. Curr Hematol Malig Rep 2019;14:187-96. [PMID: 31077067 DOI: 10.1007/s11899-019-00507-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
598 Bruserud Ø, Hansen BA, Vetti N, Johansen S, Reikvam H. Successful eradication of leptomeningeal plasma cell disease. Oxf Med Case Reports 2018;2018:omy038. [PMID: 29992033 DOI: 10.1093/omcr/omy038] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
599 Grunenberg A, Buske C. Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia. Dtsch Arztebl Int 2017;114:745-51. [PMID: 29169431 DOI: 10.3238/arztebl.2017.0745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
600 Liu XL, Yang PY, Yu XY, Chen JC, Liu XL, Bai J, Liu YM, He H, Sun JN, Fan HQ, Zhang C, Zhang Y, Su KJ, Liu CS, Tan YH, Gao SJ, Li W, Jin FY. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients]. Zhonghua Xue Ye Xue Za Zhi 2018;39:408-13. [PMID: 29779352 DOI: 10.3760/cma.j.issn.0253-2727.2018.05.013] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
601 Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, Ferrada MA, Wu Z, Gutierrez-Rodrigues F, Lotter J, Wilson L, Hoffmann P, Cardona DO, Patel N, Dulau-Florea A, Kastner DL, Grayson PC, Beck DB, Young NS, Calvo KR. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 2021;5:3203-15. [PMID: 34427584 DOI: 10.1182/bloodadvances.2021004976] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
602 Hemke R, Yang K, Husseini J, Bredella MA, Simeone FJ. Organ dose and total effective dose of whole-body CT in multiple myeloma patients. Skeletal Radiol 2020;49:549-54. [PMID: 31612246 DOI: 10.1007/s00256-019-03292-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
603 Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N. IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica 2017;102:773-84. [PMID: 28057743 DOI: 10.3324/haematol.2016.153841] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
604 Ozaki S, Harada T, Yagi H, Sekimoto E, Shibata H, Shigekiyo T, Fujii S, Nakamura S, Miki H, Kagawa K, Abe M. Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. Cancers (Basel) 2019;12:E12. [PMID: 31861479 DOI: 10.3390/cancers12010012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
605 Zhang C, Zhang Y. Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study. J Clin Lab Anal 2020;34:e23372. [PMID: 32548852 DOI: 10.1002/jcla.23372] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
606 Kim Y, Park SS, Min CK, Lee GD, Son J, Jo SJ, Han E, Han K, Kim M. KRAS, NRAS, and BRAF mutations in plasma cell myeloma at a single Korean institute. Blood Res 2020;55:159-68. [PMID: 32989177 DOI: 10.5045/br.2020.2020137] [Reference Citation Analysis]
607 Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget 2017;8:35863-76. [PMID: 28415782 DOI: 10.18632/oncotarget.16262] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
608 Xu Z, Sun Y, Xu T, Shi Y, Liang L, Liu P, Ge J. MGUS Predicts Worse Prognosis in Patients with Coronary Artery Disease. J Cardiovasc Transl Res 2020;13:806-12. [PMID: 31900894 DOI: 10.1007/s12265-019-09950-w] [Reference Citation Analysis]
609 Romero-García R, Gómez-Jaramillo L, Mateos RM, Jiménez-Gómez G, Pedreño-Horrillo N, Foncubierta E, Rodríguez-Gutiérrez JF, Garzón S, Mora-López F, Rodríguez C, Valor LM, Campos-Caro A. Differential epigenetic regulation between the alternative promoters, PRDM1α and PRDM1β, of the tumour suppressor gene PRDM1 in human multiple myeloma cells. Sci Rep 2020;10:15899. [PMID: 32985591 DOI: 10.1038/s41598-020-72946-z] [Reference Citation Analysis]
610 Zhong H, Xie X, Xu G. Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe? Stem Cells Int 2019;2019:9401717. [PMID: 31781250 DOI: 10.1155/2019/9401717] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
611 Song Y, Chen S, Xiang W, Xiao M, Xiao H. The mechanism of treatment of multiple myeloma with metformin by way of metabolism. Arch Med Sci 2021;17:1056-63. [PMID: 34336033 DOI: 10.5114/aoms.2020.101305] [Reference Citation Analysis]
612 Yang Y, Liu Z, Wang H, Zhang G. HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma. Front Oncol 2021;11:670673. [PMID: 34178656 DOI: 10.3389/fonc.2021.670673] [Reference Citation Analysis]
613 Yanamandra U, Kumar SK. Minimal residual disease analysis in myeloma - when, why and where. Leuk Lymphoma 2018;59:1772-84. [PMID: 29019452 DOI: 10.1080/10428194.2017.1386304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
614 Shapiro YN, O'Donnell EK. Oncologist perspective: role of imaging in myeloma. Skeletal Radiol 2021. [PMID: 34272993 DOI: 10.1007/s00256-021-03856-y] [Reference Citation Analysis]
615 Zeissig MN, Zannettino ACW, Vandyke K. Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. Cancers (Basel) 2020;12:E3643. [PMID: 33291672 DOI: 10.3390/cancers12123643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
616 Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A. Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica 2017;102:1266-72. [PMID: 28385781 DOI: 10.3324/haematol.2016.160564] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
617 Audia S, Bach B, Samson M, Lakomy D, Bour JB, Burlet B, Guy J, Duvillard L, Branger M, Leguy-Seguin V, Berthier S, Michel M, Bonnotte B. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One 2018;13:e0207218. [PMID: 30408135 DOI: 10.1371/journal.pone.0207218] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
618 Sallustio F, Curci C, Solimando AG, Leone P, Pontrelli P, Gesualdo L, Vacca A, Racanelli V, Gallone A. Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy. Cancer Biol Ther 2021;22:404-12. [PMID: 34288806 DOI: 10.1080/15384047.2021.1946458] [Reference Citation Analysis]
619 Raza S, Leng S, Lentzsch S. The Critical Role of Imaging in the Management of Multiple Myeloma. Curr Hematol Malig Rep 2017;12:168-75. [PMID: 28317080 DOI: 10.1007/s11899-017-0379-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
620 Westerland OA, Pratt G, Kazmi M, El-Najjar I, Streetly M, Yong K, Morris M, Mehan R, Sambrook M, Hall-Craggs M, Silver D, Goh V. National survey of imaging practice for suspected or confirmed plasma cell malignancies. Br J Radiol 2018;91:20180462. [PMID: 30102561 DOI: 10.1259/bjr.20180462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
621 Napodano C, Pocino K, Gulli F, Colacicco L, Santini SA, Zuppi C, Basile U. Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis. J Clin Lab Anal 2017;31. [PMID: 27424526 DOI: 10.1002/jcla.22027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
622 Fonseca R, Jain T. Bone Disease in Myeloma: The Claws of CRAB. Clin Cancer Res 2016;22:1301-3. [PMID: 26792259 DOI: 10.1158/1078-0432.CCR-15-2981] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
623 Cheta J, Binder M. A Case Report of Multiple Myeloma Associated With Myeloperoxidase and Proteinase-3 Antibodies Posing a Diagnostic Dilemma. J Investig Med High Impact Case Rep 2019;7:2324709619843944. [PMID: 31043084 DOI: 10.1177/2324709619843944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
624 Hamdaoui H, Benlarroubia O, Ait Boujmia OK, Mossafa H, Ouldim K, Belkhayat A, Smyej I, Benrahma H, Dehbi H, Chegdani F. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. Mol Genet Genomic Med 2020;8:e1363. [PMID: 32573970 DOI: 10.1002/mgg3.1363] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
625 Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15:45-59. [PMID: 30510265 DOI: 10.1038/s41581-018-0077-4] [Cited by in Crossref: 138] [Cited by in F6Publishing: 117] [Article Influence: 69.0] [Reference Citation Analysis]
626 Nielsen LK, Larsen RF, Jarlbaek L, Möller S, Jespersen E. Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. Ann Hematol 2021;100:2311-23. [PMID: 33409622 DOI: 10.1007/s00277-020-04356-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
627 Elsayad K, Oertel M, König L, Hüske S, Le Ray E, Meheissen MAM, Elsaid AA, Elfaham E, Debus J, Kirova Y, Herfarth K, Eich HT. Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. Cancers (Basel) 2020;12:E676. [PMID: 32183106 DOI: 10.3390/cancers12030676] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
628 Barwick T, Orton M, Koh DM, Kaiser M, Rockall A, Tunariu N, Blackledge M, Messiou C. Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. Br J Radiol 2021;94:20200682. [PMID: 33733812 DOI: 10.1259/bjr.20200682] [Reference Citation Analysis]
629 Xu L, Yang W, Shu YF, Xu XF. Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review. J Int Med Res 2020;48:300060520920395. [PMID: 32363985 DOI: 10.1177/0300060520920395] [Reference Citation Analysis]
630 Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NWCJ, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H, Zweegman S, Moreau P, Einsele H, Boccadoro M, San Miguel J, Dimopoulos MA, Sonneveld P. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 2020;34:2000-11. [PMID: 32444866 DOI: 10.1038/s41375-020-0876-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 48.0] [Reference Citation Analysis]
631 Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100. [PMID: 26565896 DOI: 10.1002/ajh.24236] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
632 Pál I, Illés Á, Váróczy L. Multiple Myeloma of the Young - a Single Center Experience Highlights Future Directions. Pathol Oncol Res 2020;26:419-24. [PMID: 30406398 DOI: 10.1007/s12253-018-0526-1] [Reference Citation Analysis]
633 Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer 2018;18:1152. [PMID: 30463534 DOI: 10.1186/s12885-018-5015-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
634 Sachpekidis C, Türk M, Dimitrakopoulou-Strauss A. Quantitative, Dynamic 18F-FDG PET/CT in Monitoring of Smoldering Myeloma: A Case Report. Diagnostics (Basel) 2021;11:649. [PMID: 33916783 DOI: 10.3390/diagnostics11040649] [Reference Citation Analysis]
635 Purushothaman A, Bandari SK, Liu J, Mobley JA, Brown EE, Sanderson RD. Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. J Biol Chem. 2016;291:1652-1663. [PMID: 26601950 DOI: 10.1074/jbc.m115.686295] [Cited by in Crossref: 127] [Cited by in F6Publishing: 81] [Article Influence: 21.2] [Reference Citation Analysis]
636 Mateos MV, Fink L, Koneswaran N, Intorcia M, Giannopoulou C, Niepel D, Cavo M. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. BMC Cancer 2020;20:170. [PMID: 32126974 DOI: 10.1186/s12885-020-6596-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
637 Hofmann JN, Landgren O, Landy R, Kemp TJ, Santo L, McShane CM, Shearer JJ, Lan Q, Rothman N, Pinto LA, Pfeiffer RM, Hildesheim A, Katki HA, Purdue MP. A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. JNCI Cancer Spectr 2020;4:pkz104. [PMID: 33336146 DOI: 10.1093/jncics/pkz104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
638 Feigerlová E, Battaglia-Hsu SF. Cytokines in Endocrine Dysfunction of Plasma Cell Disorders. Mediators Inflamm 2017;2017:7586174. [PMID: 28740334 DOI: 10.1155/2017/7586174] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
639 Kawashima I, Takano K, Kumagai T, Koshiishi M, Oishi S, Sueki Y, Nakajima K, Mitsumori T, Kirito K. Combined Coagulopathy Can Induce Both Hemorrhagic and Thrombotic Complications in Multiple Myeloma. Intern Med 2018;57:3303-6. [PMID: 29984746 DOI: 10.2169/internalmedicine.0915-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
640 Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, Dispenzieri A, Kapoor P, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Kyle RA, Rajkumar SV, Kumar SK. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk 2020;20:596-601. [PMID: 32360276 DOI: 10.1016/j.clml.2020.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Norrasethada L, Khumpoo W, Rattarittamrong E, Rattanathammethee T, Chai-Adisaksopha C, Tantiworawit A. The use of mean platelet volume for distinguishing the causes of thrombocytopenia in adult patients. Hematol Rep 2019;11:7732. [PMID: 30996849 DOI: 10.4081/hr.2019.7732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
642 Dove E, Kowalewska J. Educational Case: Nephrotic Syndrome in Older Adult. Acad Pathol 2020;7:2374289520944554. [PMID: 32875062 DOI: 10.1177/2374289520944554] [Reference Citation Analysis]
643 Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol 2017;12:643-54. [PMID: 28803351 DOI: 10.1007/s11523-017-0524-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
644 Lutz R, Friedrich M, Raab MS, Weinhold N, Goldschmidt H. Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop. Cancers (Basel) 2021;13:4135. [PMID: 34439297 DOI: 10.3390/cancers13164135] [Reference Citation Analysis]
645 San-Miguel JF, Kantarjian HM. Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment. Nat Rev Clin Oncol 2015;12:71-2. [PMID: 25511190 DOI: 10.1038/nrclinonc.2014.216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
646 Schoninger S, Homsi Y, Kreps A, Milojkvovic N. A Case of Multiple Myeloma Misdiagnosed as Seronegative Rheumatoid Arthritis and Review of Relevant Literature. Case Rep Rheumatol 2018;2018:9746241. [PMID: 30405932 DOI: 10.1155/2018/9746241] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
647 Berdeja JG, Gregory TK, Faber EA, Hart LL, Mace JR, Arrowsmith ER, Flinn IW, Matous JV. A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Am J Hematol 2021;96:428-35. [PMID: 33421178 DOI: 10.1002/ajh.26088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
648 Zahran AM, Zahran ZAM, Rayan A. Microparticles and PD1 interplay added a prognostic impact in treatment outcomes of patients with multiple myeloma. Sci Rep 2021;11:17681. [PMID: 34480060 DOI: 10.1038/s41598-021-96975-4] [Reference Citation Analysis]
649 Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, Emanuel M, Petrosyan A, Bhutani M, Calvo KR, Dulau-Florea A, Kwok M, Lee MJ, Lee S, Lindenberg L, Mailankody S, Manasanch E, Maric I, Mena E, Patel N, Tageja N, Trepel JB, Turkbey B, Wang HW, Wang W, Yuan C, Zhang Y, Braylan R, Choyke P, Stetler-Stevenson M, Steinberg SM, Figg WD Sr, Roschewski M, Landgren O. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial. JAMA Oncol 2021. [PMID: 34529025 DOI: 10.1001/jamaoncol.2021.3971] [Reference Citation Analysis]
650 Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020;383:2628-38. [PMID: 33108101 DOI: 10.1056/NEJMoa2026834] [Cited by in Crossref: 68] [Cited by in F6Publishing: 23] [Article Influence: 68.0] [Reference Citation Analysis]
651 Vaxman I, Sidiqi MH, Al Saleh AS, Kumar S, Muchtar E, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Hogan W, Gertz M. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplant 2021;56:928-35. [PMID: 33208916 DOI: 10.1038/s41409-020-01136-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
652 Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Exp Hematol Oncol 2015;5:1. [PMID: 26740908 DOI: 10.1186/s40164-015-0030-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
653 Nasr F, Ghoche AA, Diab S, Nasr L, Ammanouil E, Riachy C, Hallit S, Chahine G. Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study. Leuk Res Rep 2021;15:100252. [PMID: 34141564 DOI: 10.1016/j.lrr.2021.100252] [Reference Citation Analysis]
654 Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F. Interest of Pet Imaging in Multiple Myeloma. Front Med (Lausanne) 2019;6:69. [PMID: 31024917 DOI: 10.3389/fmed.2019.00069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
655 Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer 2017;17:543-56. [PMID: 28835722 DOI: 10.1038/nrc.2017.63] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
656 Clark KC, Hewett DR, Panagopoulos V, Plakhova N, Opperman KS, Bradey AL, Mrozik KM, Vandyke K, Mukherjee S, Davies GCG, Worthley DL, Zannettino ACW. Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. Cancers (Basel) 2020;12:E2149. [PMID: 32756430 DOI: 10.3390/cancers12082149] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
657 Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J 2020;10:106. [PMID: 33097687 DOI: 10.1038/s41408-020-00369-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
658 Al-Katib AM, Gaith H, Sano D, Al-Katib S, Bonnett M, Kafri Z. Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy. Clin Case Rep 2020;8:1797-801. [PMID: 32983498 DOI: 10.1002/ccr3.3019] [Reference Citation Analysis]
659 Seefried L, Genest F, Strömsdörfer J, Engelmann B, Lapa C, Jakob F, Baumann FT, Sperlich B, Jundt F. Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. J Bone Oncol 2020;25:100323. [PMID: 33083217 DOI: 10.1016/j.jbo.2020.100323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
660 Bai J, Yang Y, Wang J, Zhang L, Wang F, He A. Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma. Clin Proteomics 2019;16:17. [PMID: 31043929 DOI: 10.1186/s12014-019-9238-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
661 Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, Bos G, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden A, Deenik W, Coenen J, Hinge M, Klein S, Tanis B, Szatkowski D, Brouwer R, Westerman M, Leys R, Sinnige H, Haukås E, van der Hem K, Durian M, Gimsing P, van de Donk N, Sonneveld P, Waage A, Abildgaard N, Zweegman S. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica 2020;105:1650-9. [PMID: 31515355 DOI: 10.3324/haematol.2019.222299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
662 Gavriatopoulou M, Βoultadaki A, Koutoulidis V, Ntanasis-Stathopoulos I, Bourgioti C, Malandrakis P, Fotiou D, Migkou M, Kanellias N, Eleutherakis-Papaiakovou E, Kastritis E, Terpos E, Dimopoulos MA, Moulopoulos LA. The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. Blood Cancer J 2020;10:93. [PMID: 32978365 DOI: 10.1038/s41408-020-00360-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
663 Serin I, Pehlivan S, Gundes I, Fidan Oyaci Y, Pehlivan M. A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism. Ann Hematol 2021;100:421-7. [PMID: 33170343 DOI: 10.1007/s00277-020-04339-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Hoering A, Durie B, Wang H, Crowley J. End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. Future Oncol 2017;13:1181-93. [PMID: 28395525 DOI: 10.2217/fon-2016-0504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
665 Antlanger M, Dust T, Reiter T, Böhm A, Lamm WW, Gornicec M, Willenbacher E, Nachbaur D, Weger R, Rabitsch W, Rasoul-Rockenschaub S, Worel N, Lechner D, Greinix H, Keil F, Gisslinger H, Agis H, Krauth MT. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer 2018;18:1008. [PMID: 30342509 DOI: 10.1186/s12885-018-4926-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
666 Zambello R, Crimì F, Lico A, Barilà G, Branca A, Guolo A, Varin C, Vezzaro R, Checuz L, Scapin V, Berno T, Pizzi M, Ponzoni A, De Biasi E, Vio S, Semenzato G, Zucchetta P, Lacognata C. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. Ann Hematol 2019;98:679-89. [PMID: 30539276 DOI: 10.1007/s00277-018-3555-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
667 Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia 2018;32:1404-13. [PMID: 29784907 DOI: 10.1038/s41375-018-0133-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
668 Devarakonda S, Cottini F, Bumma N, Khan A, Sharma N, Chaudhry M, Benson D, Rosko A, Efebera Y. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. J Clin Med 2020;9:E3626. [PMID: 33187184 DOI: 10.3390/jcm9113626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
669 Lomas OC, Mouhieddine TH, Tahri S, Ghobrial IM. Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers (Basel). 2020;12. [PMID: 32545521 DOI: 10.3390/cancers12061554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
670 Oostvogels R, Jak M, Raymakers R, Mous R, Minnema MC. Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. Br J Haematol 2018;183:60-7. [PMID: 30080247 DOI: 10.1111/bjh.15504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
671 Rapanotti MC, Franceschini L, Viguria TMS, Ialongo C, Fraboni D, Cerretti R, De Angelis G, Pupo L, Rizzo M, Cantonetti M, Postorino M, Voso MT, Lo-Coco F. Molecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to İnvestigate Disease Progression. Mediterr J Hematol Infect Dis 2018;10:e2018059. [PMID: 30416691 DOI: 10.4084/MJHID.2018.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
672 Anderson KC. Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv 2017;1:517-21. [PMID: 29296970 DOI: 10.1182/bloodadvances.2016000117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
673 Pendón-Ruiz de Mier MV, Ojeda R, Álvarez-Lara MA, Navas A, Alonso C, Caballero-Villarraso J, Aljama P, Álvarez MA, Soriano S, Rodríguez M, Martín-Malo A. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. BMC Nephrol 2020;21:227. [PMID: 32539688 DOI: 10.1186/s12882-020-01885-8] [Reference Citation Analysis]
674 Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res 2019;25:478-86. [PMID: 30279233 DOI: 10.1158/1078-0432.CCR-18-1325] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
675 Rundgren IM, Ersvær E, Ahmed AB, Ryningen A, Bruserud Ø. Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. BMC Immunol 2019;20:39. [PMID: 31703617 DOI: 10.1186/s12865-019-0323-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
676 Sethi S, Rajkumar SV, D'Agati VD. The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. J Am Soc Nephrol 2018;29:1810-23. [PMID: 29703839 DOI: 10.1681/ASN.2017121319] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 22.7] [Reference Citation Analysis]
677 Barwick T, Bretsztajn L, Wallitt K, Amiras D, Rockall A, Messiou C. Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol 2019;92:20180768. [PMID: 30604631 DOI: 10.1259/bjr.20180768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
678 Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 2016;6:e454. [PMID: 27471870 DOI: 10.1038/bcj.2016.65] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
679 Halvarsson BM, Wihlborg AK, Ali M, Lemonakis K, Johnsson E, Niroula A, Cibulskis C, Weinhold N, Försti A, Alici E, Langer C, Pfreundschuh M, Goldschmidt H, Mellqvist UH, Turesson I, Waage A, Hemminki K, Golub T, Nahi H, Gullberg U, Hansson M, Nilsson B. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv 2017;1:619-23. [PMID: 29296704 DOI: 10.1182/bloodadvances.2016003111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
680 Cherniawsky HM, Kukreti V, Reece D, Masih-Khan E, McCurdy A, Jimenez-Zepeda VH, Sebag M, Song K, White D, Stakiw J, LeBlanc R, Reiman A, Aslam M, Louzada M, Kotb R, Gul E, Atenafu E, Venner CP. The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. Haematologica 2021;106:1733-6. [PMID: 33054120 DOI: 10.3324/haematol.2020.259093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
681 Abdullah HMA, Ellithi M, Waqas Q, Cunningham A, Oliver T. Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man. BMJ Case Rep 2019;12:e229070. [PMID: 31383675 DOI: 10.1136/bcr-2018-229070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
682 Ashour R, Ri M, Aly SS, Yoshida T, Tachita T, Kanamori T, Aoki S, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Komatsu H, Mansour S, Elsaied AA, Iida S. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma. Int J Hematol 2019;110:69-76. [PMID: 31115879 DOI: 10.1007/s12185-019-02649-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
683 Zhang LL, Cao XX, Shen KN, Han HX, Zhang CL, Qiu Y, Zhao H, Gao XM, Feng J, Zhang L, Zhou DB, Li J. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. Ann Hematol 2020;99:1735-40. [PMID: 32535708 DOI: 10.1007/s00277-020-04123-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
684 Pan Q, Cao X, Luo Y, Li J, Feng J, Li F. Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2020;47:537-46. [PMID: 31776631 DOI: 10.1007/s00259-019-04605-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
685 Beksac M, Seval GC, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 2020;105:201-8. [PMID: 31278209 DOI: 10.3324/haematol.2019.219295] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
686 Landgren O. Shall we treat smoldering multiple myeloma in the near future? Hematology Am Soc Hematol Educ Program 2017;2017:194-204. [PMID: 29222256 DOI: 10.1182/asheducation-2017.1.194] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
687 Colombo M, Galletti S, Garavelli S, Platonova N, Paoli A, Basile A, Taiana E, Neri A, Chiaramonte R. Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget 2015;6:26826-40. [PMID: 26308486 DOI: 10.18632/oncotarget.5025] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
688 Westerland O, Amlani A, Kelly-Morland C, Fraczek M, Bailey K, Gleeson M, El-Najjar I, Streetly M, Bassett P, Cook GJR, Goh V; Myeloma Imaging Research Group at Guy’s & St Thomas’ Hospital, London and King’s College London. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. Eur J Nucl Med Mol Imaging 2021;48:2558-65. [PMID: 33469686 DOI: 10.1007/s00259-020-05182-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
689 Menè P, Moioli A, Stoppacciaro A, Lai S, Festuccia F. Acute Kidney Injury in Monoclonal Gammopathies. J Clin Med 2021;10:3871. [PMID: 34501317 DOI: 10.3390/jcm10173871] [Reference Citation Analysis]
690 Mehtat Ünlü Ş, Özsan H, Sarıoğlu S. The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance. Turk J Haematol 2017;34:282-8. [PMID: 28832010 DOI: 10.4274/tjh.2017.0197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
691 Schmalzing M, Tony HP, Knop S. [Monoclonal gammopathy of undetermined significance and multiple myeloma]. Z Rheumatol 2017;76:33-7. [PMID: 29330758 DOI: 10.1007/s00393-017-0335-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
692 Pei XJ, Lian YF, Yan YC, Jiang T, Liu AJ, Shi QL, Pan ZY. Fat fraction quantification of lumbar spine: comparison of T1-weighted two-point Dixon and single-voxel magnetic resonance spectroscopy in diagnosis of multiple myeloma. Diagn Interv Radiol 2020;26:492-7. [PMID: 32755881 DOI: 10.5152/dir.2020.19401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
693 Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol 2017;35:2911-8. [PMID: 28686535 DOI: 10.1200/JCO.2017.72.2975] [Cited by in Crossref: 133] [Cited by in F6Publishing: 70] [Article Influence: 33.3] [Reference Citation Analysis]
694 Manzotti G, Ciarrocchi A, Sancisi V. Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers (Basel) 2019;11:E304. [PMID: 30841549 DOI: 10.3390/cancers11030304] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
695 Ibekwe E, Horsley NB, Jiang L, Achenjang NS, Anudu A, Akhtar Z, Chornenka KG, Monohan GP, Chornenkyy YG. Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma. J Clin Med 2018;7:E253. [PMID: 30177596 DOI: 10.3390/jcm7090253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
696 Yu X, Bao J, Cui X, DU F, Wang Y, Bi L, Sun J, Li L. Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apoptosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein. Iran J Public Health 2020;49:2078-86. [PMID: 33708728 DOI: 10.18502/ijph.v49i11.4723] [Reference Citation Analysis]
697 De Martinis M, Allegra A, Sirufo MM, Tonacci A, Pioggia G, Raggiunti M, Ginaldi L, Gangemi S. Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review. Int J Mol Sci 2021;22:8855. [PMID: 34445560 DOI: 10.3390/ijms22168855] [Reference Citation Analysis]
698 He Y, Jiang D, Zhang K, Zhu Y, Zhang J, Wu X, Xia J, Zhu Y, Zou L, Hu J, Cui Y, Zhou W, Chen F. Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy. J Cancer 2021;12:6198-208. [PMID: 34539893 DOI: 10.7150/jca.61602] [Reference Citation Analysis]
699 Vij R, Fowler KJ, Shokeen M. New Approaches to Molecular Imaging of Multiple Myeloma. J Nucl Med 2016;57:1-4. [PMID: 26541780 DOI: 10.2967/jnumed.115.163808] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
700 Parker AR, Berlanga O, Harding S. Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy". Biomed Res Int 2015;2015:742762. [PMID: 25861645 DOI: 10.1155/2015/742762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
701 Zhang W, Cao L, Liu X, He X, Zhang Y, Yang Z, Yang P, Wang J, Hu K, Zhang X, Liu W, Yuan X, Jing H. High expression of CHML predicts poor prognosis of multiple myeloma. J Cancer 2019;10:6048-56. [PMID: 31762814 DOI: 10.7150/jca.34465] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
702 Kulikowska de Nałęcz A, Ciszak L, Usnarska-Zubkiewicz L, Frydecka I, Pawlak E, Szmyrka M, Kosmaczewska A. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. Int J Mol Sci 2021;22:9298. [PMID: 34502204 DOI: 10.3390/ijms22179298] [Reference Citation Analysis]
703 Zhou L, Qi S, Yan C, Jin HM, Xu J, Ma L, Guan J, Xia S. [Myeloid-derived suppressor cells in peripheral blood of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2017;38:545-7. [PMID: 28655102 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.016] [Reference Citation Analysis]
704 Mesguich C, Zanotti-Fregonara P, Hindié E. New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. Theranostics 2016;6:287-90. [PMID: 26877786 DOI: 10.7150/thno.14400] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
705 Junejo S, Ali Y, Singh Lubana S, Tuli SS. Diffuse Peritoneal and Bowel Wall Infiltration by Light Chain-AL Amyloidosis with Omental Calcification Mimicking Abdominal Carcinomatosis - An Elderly Female with Incidental Finding of Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS). Am J Case Rep 2017;18:1247-50. [PMID: 29176541 DOI: 10.12659/ajcr.907041] [Reference Citation Analysis]
706 Ma L, Xu S, Qu J, Hou J, Wang Y, Wen L, Liu Y, Kang Y, Jiang M, Fu W, Du J, Zhou L, Huang X, Zhang Z, Lu J; Chinese medical doctor association multiple myeloma professional committee, Academic working group on multiple myeloma of Chinese geriatric medical association. Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. Hematol Oncol 2019;37:75-9. [PMID: 30117173 DOI: 10.1002/hon.2548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
707 Trejos T AM, Cuartas M MC, Korenfeld K Y, Cardona Q R. Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma. Radiol Case Rep 2020;15:2589-93. [PMID: 33082903 DOI: 10.1016/j.radcr.2020.09.050] [Reference Citation Analysis]
708 Fenton A, Chinnadurai R, Gullapudi L, Kampanis P, Dasgupta I, Ritchie J, Harding S, Ferro CJ